BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105. [PMID: 16997664 DOI: 10.1016/s0140-6736(06)69420-8] [Cited by in Crossref: 1062] [Cited by in F6Publishing: 1183] [Article Influence: 66.4] [Reference Citation Analysis]
Number Citing Articles
1 Üstünsoy S. Resistin as a Biomarker and Applications to Prediabetes. Biomarkers in Diabetes 2023. [DOI: 10.1007/978-3-031-08014-2_4] [Reference Citation Analysis]
2 Albrahim T. Lycopene Modulates Oxidative Stress and Inflammation in Hypercholesterolemic Rats. Pharmaceuticals 2022;15:1420. [DOI: 10.3390/ph15111420] [Reference Citation Analysis]
3 Kabisch S, Meyer NMT, Honsek C, Kemper M, Gerbracht C, Arafat AM, Dambeck U, Osterhoff MA, Weickert MO, Pfeiffer AFH. Predicting Factors for Metabolic Non-Response to a Complex Lifestyle Intervention—A Replication Analysis to a Randomized-Controlled Trial. Nutrients 2022;14:4721. [DOI: 10.3390/nu14224721] [Reference Citation Analysis]
4 Lundin M, Ferrannini G, Mellbin L, Johansson I, Norhammar A, Näsman P, Shahim B, Smetana S, Venkateshvaran A, Wang A, Sörensson P, Rydén L. SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI). Diabetes Research and Clinical Practice 2022;193:110141. [DOI: 10.1016/j.diabres.2022.110141] [Reference Citation Analysis]
5 Lee YS, Joo JH, Park EC. Association between Nighttime Work and HbA1c Levels in South Korea. Healthcare (Basel) 2022;10:1977. [PMID: 36292424 DOI: 10.3390/healthcare10101977] [Reference Citation Analysis]
6 Ren X, Sun Y, Guo Q, Liu H, Jiang H, He X, Li X, Shi X, Xiu Z, Dong Y. Ameliorating Effect of the Total Flavonoids of Morus nigra L. on Prediabetic Mice Based on Regulation of Inflammation and Insulin Sensitization. J Agric Food Chem 2022. [PMID: 36150176 DOI: 10.1021/acs.jafc.2c04970] [Reference Citation Analysis]
7 Nwosu BU. The Progression of Prediabetes to Type 2 Diabetes in Children and Adolescents in the United States: Current Challenges and Solutions. Endocrines 2022;3:545-551. [DOI: 10.3390/endocrines3030045] [Reference Citation Analysis]
8 Xuan Q, Hu C, Zhang Y, Wang Q, Zhao X, Liu X, Wang C, Jia W, Xu G. Serum lipidomics profiles reveal potential lipid markers for prediabetes and type 2 diabetes in patients from multiple communities. Front Endocrinol 2022;13:966823. [DOI: 10.3389/fendo.2022.966823] [Reference Citation Analysis]
9 Koniari I, Velissaris D, Kounis NG, Koufou E, Artopoulou E, de Gregorio C, Mplani V, Paraskevas T, Tsigkas G, Hung M, Plotas P, Lambadiari V, Ikonomidis I. Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. JCM 2022;11:4660. [DOI: 10.3390/jcm11164660] [Reference Citation Analysis]
10 Schütt K, Aberle J, Bauersachs J, Birkenfeld A, Frantz S, Ganz M, Jacob S, Kellerer M, Leschke M, Liebetrau C, Marx N, Müller-wieland D, Raake P, Schulze PC, Tschöpe D, von Haehling S, Zelniker TA, Forst T. Positionspapier Herzinsuffizienz und Diabetes. Diabetologie und Stoffwechsel 2022;17:277-288. [DOI: 10.1055/a-1867-3026] [Reference Citation Analysis]
11 Fisher M. Glitazones and Glitazars. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch12] [Reference Citation Analysis]
12 Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O. Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics 2022;14:1180. [DOI: 10.3390/pharmaceutics14061180] [Reference Citation Analysis]
13 Pazos-couselo M, Portos-regueiro C, González-rodríguez M, Manuel García-lopez J, Alonso-sampredro M, Rodríguez-gonzález R, Fernández-merino C, Gude F. Aging of Glucose Profiles in an Adult Population without Diabetes. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109929] [Reference Citation Analysis]
14 Napoli R, D’assante R, Miniero M, Salzano A, Cittadini A. Anabolic Deficiencies in Heart Failure. Cardiology Clinics 2022;40:149-59. [DOI: 10.1016/j.ccl.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ho Y, Ranasinghe P. A bibliometric analysis of highly cited insulin resistance publications in Science Citation Index Expanded. Obesity Medicine 2022;31:100399. [DOI: 10.1016/j.obmed.2022.100399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhu L, Huang Q, Li X, Jin B, Ding Y, Chou CJ, Su K, Zhang Y, Chen X, Hwa KY, Thyparambil S, Liao W, Han Z, Mortensen R, Jin Y, Li Z, Schilling J, Li Z, Sylvester KG, Sun X, Ling XB. Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus. Front Mol Biosci 2022;9:841209. [DOI: 10.3389/fmolb.2022.841209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ho CC, Yang YS, Huang CN, Lo SC, Wang YH, Kornelius E. The efficacy of pioglitazone for renal protection in diabetic kidney disease. PLoS One 2022;17:e0264129. [PMID: 35176115 DOI: 10.1371/journal.pone.0264129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Davidson MB. Historical Review of the Diagnosis of Prediabetes/Intermediate Hyperglycemia: Case for the International Criteria. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109219] [Reference Citation Analysis]
19 Yin Y, Tu Y, Zhao M, Tang W. Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis. Int J Environ Res Public Health 2022;19:1622. [PMID: 35162645 DOI: 10.3390/ijerph19031622] [Reference Citation Analysis]
20 Ren X, Xing Y, He L, Xiu Z, Yang L, Han A, Jia Q, Dong Y. Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota study. J Ethnopharmacol 2022;:115029. [PMID: 35077826 DOI: 10.1016/j.jep.2022.115029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Luo Y, Wang H, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Paul SK. A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. J Diabetes Res 2022;2022:2971382. [PMID: 35036447 DOI: 10.1155/2022/2971382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S39-45. [PMID: 34964876 DOI: 10.2337/dc22-S003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
23 Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Demets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-rotter R, Toto RD, Wheeler DC, Mcmurray JJV, Heerspink HJL. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. The Lancet Diabetes & Endocrinology 2022;10:24-34. [DOI: 10.1016/s2213-8587(21)00295-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
24 Üstünsoy S. Resistin As a Biomarker and Applications to PreDiabetes. Biomarkers in Diabetes 2022. [DOI: 10.1007/978-3-030-81303-1_4-1] [Reference Citation Analysis]
25 Cheng AYY. SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes. The Lancet Diabetes & Endocrinology 2022;10:2-3. [DOI: 10.1016/s2213-8587(21)00310-7] [Reference Citation Analysis]
26 Kawa LB. Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea. JDM 2022;12:87-97. [DOI: 10.4236/jdm.2022.122009] [Reference Citation Analysis]
27 Liu Z, Li P, Yin H, Li M, Yan J, Ma C, Ding H, Li Q, Huang Z, Yan Y, Kou C, Hu M, Wen J, Chen S, Jia C, Huang Y, Xu G. Future Trends in Disability and Its Determinants Among Chinese Community Patients With Anxiety Disorders: Evidence From a 5-Year Follow-Up Study. Front Psychiatry 2021;12:777236. [PMID: 34955923 DOI: 10.3389/fpsyt.2021.777236] [Reference Citation Analysis]
28 Panevin TS, Eliseev MS, Nasonov EL. Urate-lowering drugs in the treatment of gout: The unknown about the known. Naučno-praktičeskaâ revmatologiâ 2021;59:727-737. [DOI: 10.47360/1995-4484-2021-727-737] [Reference Citation Analysis]
29 Kohlenberg J, Vella A. “Is Prediabetes a Risk Factor or Is It a Disease?”. Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch1] [Reference Citation Analysis]
30 Kaur N, Majumdar V, Nagarathna R, Malik N, Anand A, Nagendra HR. Diabetic yoga protocol improves glycemic, anthropometric and lipid levels in high risk individuals for diabetes: a randomized controlled trial from Northern India. Diabetol Metab Syndr 2021;13:149. [PMID: 34949227 DOI: 10.1186/s13098-021-00761-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. Annu Rev Public Health 2021;42:59-77. [PMID: 33355476 DOI: 10.1146/annurev-publhealth-090419-102644] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
32 Liu Y, Guo H, Wang Q, Chen J, Xuan Y, Xu J, Liu Y, Sun K, Gao Q, Sun Z, Wang B. Short-term effects of lifestyle intervention in the reversion to normoglycemia in people with prediabetes. Prim Care Diabetes 2021:S1751-9918(21)00225-4. [PMID: 34930688 DOI: 10.1016/j.pcd.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Skwiersky S, Iwuala S, Chillumuntala S, Osafehinti D, Karam J. Renin Angiotensin Aldosterone System, Glucose Homeostasis, and Prevention of Type 2 Diabetes: Mechanistic Insights and Evidence from Major Clinical Trials. Renin-Angiotensin Aldosterone System 2021. [DOI: 10.5772/intechopen.97737] [Reference Citation Analysis]
34 Morgunova TB, Glinkina IV, Fadeev VV. Prediabetes: challenges and opportunities. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-12-220-227] [Reference Citation Analysis]
35 Jonas DE, Crotty K, Yun JDY, Middleton JC, Feltner C, Taylor-Phillips S, Barclay C, Dotson A, Baker C, Balio CP, Voisin CE, Harris RP. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021;326:744-60. [PMID: 34427595 DOI: 10.1001/jama.2021.10403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
36 Escalada San Martín J. Prediabetes: what are we talking about? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:305-308. [DOI: 10.1515/almed-2021-0034] [Reference Citation Analysis]
37 Escalada San Martín J. Prediabetes ¿de qué estamos hablando? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:309-312. [DOI: 10.1515/almed-2021-0030] [Reference Citation Analysis]
38 Kim WJ. Recent Perspective on Thiazolidinedione. J Korean Diabetes 2021;22:97-104. [DOI: 10.4093/jkd.2021.22.2.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Xu B, Xing A, Li S. The forgotten type 2 diabetes mellitus medicine: rosiglitazone. Diabetol Int 2022;13:49-65. [DOI: 10.1007/s13340-021-00519-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Woo M, Kim M. Insulin sensitization causes accelerated sinus nodal dysfunction through autophagic dysregulation in hypertensive mice. Transl Clin Pharmacol 2021;29:92-106. [PMID: 34235122 DOI: 10.12793/tcp.2021.29.e9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Giráldez-García C, Cea-Soriano L, Albaladejo R, Franch-Nadal J, Mata-Cases M, Díez-Espino J, Artola S, Serrano R, Regidor E; PREDAPS Study Group. The heterogeneity of reversion to normoglycemia according to prediabetes type is not explained by lifestyle factors. Sci Rep 2021;11:9667. [PMID: 33958606 DOI: 10.1038/s41598-021-87838-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yoon SY, Yu JS, Hwang JY, So HM, Seo SO, Kim JK, Jang TS, Chung SJ, Kim KH. Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance. Molecules 2021;26:1612. [PMID: 33799458 DOI: 10.3390/molecules26061612] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Twickler MTB, Regieli J, Grobben R, Hart EA, Tesselaar ME, Meijer RCA, Chamuleau SAJ, Nathoe HM. Impact of Endocrine Disorders on the Heart. Endocrinology 2021. [DOI: 10.1007/978-3-319-68729-2_3] [Reference Citation Analysis]
44 Won JC. Thiazolidinediones (TZDs). Stroke Revisited 2021. [DOI: 10.1007/978-981-16-5123-6_11] [Reference Citation Analysis]
45 Inaishi J, Saisho Y. Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review. Nutrients 2020;12:E3846. [PMID: 33339276 DOI: 10.3390/nu12123846] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
46 Munshi MN, Meneilly GS, Rodríguez-Mañas L, Close KL, Conlin PR, Cukierman-Yaffe T, Forbes A, Ganda OP, Kahn CR, Huang E, Laffel LM, Lee CG, Lee S, Nathan DM, Pandya N, Pratley R, Gabbay R, Sinclair AJ. Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol 2020;8:855-67. [PMID: 32946822 DOI: 10.1016/S2213-8587(20)30230-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
47 Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab 2021;106:e1420-32. [PMID: 32995892 DOI: 10.1210/clinem/dgaa692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
48 Esser N, Utzschneider KM, Kahn SE. Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia 2020;63:2007-21. [PMID: 32894311 DOI: 10.1007/s00125-020-05245-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 24.5] [Reference Citation Analysis]
49 Chen Y, Shen T, Zhong L, Liu Z, Dong X, Huang T, Wang Q, Xiao H. Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Front Pharmacol 2020;11:1167. [PMID: 32848774 DOI: 10.3389/fphar.2020.01167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
50 Ha J, Sherman A. Type 2 diabetes: one disease, many pathways. Am J Physiol Endocrinol Metab 2020;319:E410-26. [PMID: 32663101 DOI: 10.1152/ajpendo.00512.2019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
51 Jeong YJ, Hwang MJ, Hong CO, Yoo DS, Kim JS, Kim DY, Lee KW. Anti-hyperglycemic and hypolipidemic effects of black ginseng extract containing increased Rh4, Rg5, and Rk1 content in muscle and liver of type 2 diabetic db/db mice. Food Sci Biotechnol 2020;29:1101-12. [PMID: 32670664 DOI: 10.1007/s10068-020-00753-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
52 Adriana Stoica R, Simona Ștefan D, Rizzo M, Iulia Suceveanu A, Paul Suceveanu A, Serafinceanu C, Pantea-stoian A. Metformin Indications, Dosage, Adverse Reactions, and Contraindications. Metformin 2020. [DOI: 10.5772/intechopen.88675] [Reference Citation Analysis]
53 Phuphuakrat A, Nimitphong H, Reutrakul S, Sungkanuparph S. Prediabetes among HIV-infected individuals receiving antiretroviral therapy: prevalence, diagnostic tests, and associated factors. AIDS Res Ther 2020;17:25. [PMID: 32448349 DOI: 10.1186/s12981-020-00284-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Monnier L, Colette C, Schlienger J, Halimi S. Les méta-analyses en recherche clinique : forces et faiblesses. Médecine des Maladies Métaboliques 2020;14:239-249. [DOI: 10.1016/j.mmm.2019.12.011] [Reference Citation Analysis]
55 Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019;40:1447-67. [PMID: 31050706 DOI: 10.1210/er.2018-00141] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 57.5] [Reference Citation Analysis]
56 Gabriel R, Boukichou Abdelkader N, Acosta T, Gilis-Januszewska A, Gómez-Huelgas R, Makrilakis K, Kamenov Z, Paulweber B, Satman I, Djordjevic P, Alkandari A, Mitrakou A, Lalic N, Colagiuri S, Lindström J, Egido J, Natali A, Pastor JC, Teuschl Y, Lind M, Silva L, López-Ridaura R, Tuomilehto J; e-PREDICE Consortium. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One 2020;15:e0231196. [PMID: 32282852 DOI: 10.1371/journal.pone.0231196] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
57 Ostroumova OD, Goloborodova IV. Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure). Bezopasnost' i risk farmakoterapii 2020;8:23-35. [DOI: 10.30895/2312-7821-2020-8-1-23-35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Sallar A, Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: State of the science. Exp Biol Med (Maywood) 2020;245:889-96. [PMID: 32212859 DOI: 10.1177/1535370220915644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
59 Rodgers LR, Dennis JM, Shields BM, Mounce L, Fisher I, Hattersley AT, Henley WE; MASTERMIND Consortium. Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study. J Clin Epidemiol 2020;122:78-86. [PMID: 32194148 DOI: 10.1016/j.jclinepi.2020.03.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
60 Magge SN, Silverstein J, Elder D, Nadeau K, Hannon TS. Evaluation and Treatment of Prediabetes in Youth. J Pediatr. 2020;219:11-22. [PMID: 32143933 DOI: 10.1016/j.jpeds.2019.12.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
61 Tran P, Banerjee P. Iatrogenic Decompensated Heart Failure. Curr Heart Fail Rep 2020;17:21-7. [PMID: 32086714 DOI: 10.1007/s11897-020-00452-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Farooqi MAM, Gerstein H, Yusuf S, Leong DP. Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals. J Am Heart Assoc 2020;9:e014686. [PMID: 31986990 DOI: 10.1161/JAHA.119.014686] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
63 Vargas-Ortiz K, Lira-Mendiola G, Gómez-Navarro CM, Padilla-Estrada K, Angulo-Romero F, Hernández-Márquez JM, Villa-Martínez AK, González-Mena JN, Macías-Cervantes MH, Reyes-Escogido ML, Guardado-Mendoza R. Effect of a family and interdisciplinary intervention to prevent T2D: randomized clinical trial. BMC Public Health 2020;20:97. [PMID: 31969136 DOI: 10.1186/s12889-020-8203-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Kim JD, Lee W. Prevention of Type 2 Diabetes. Cardiovasc Prev Pharmacother 2020;2:63. [DOI: 10.36011/cpp.2020.2.e10] [Reference Citation Analysis]
65 Knowler WC, Crandall JP. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Curr Diab Rep 2019;19:154. [PMID: 31792721 DOI: 10.1007/s11892-019-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep 2019;19:151. [PMID: 31776781 DOI: 10.1007/s11892-019-1270-y] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 32.3] [Reference Citation Analysis]
67 Harreiter J, Roden M. [Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. Wien Klin Wochenschr 2019;131:6-15. [PMID: 30980151 DOI: 10.1007/s00508-019-1450-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 18.0] [Reference Citation Analysis]
68 Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res 2018;122:1135-50. [PMID: 29650631 DOI: 10.1161/CIRCRESAHA.118.311912] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
69 Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55. [PMID: 31470636 DOI: 10.3390/medicina55090546] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
70 Iskandar S, Migahid A, Kamal D, Megahed O, DeFronzo RA, Zirie M, Jayyousi A, Al Jaidah M, Abdul-Ghani M. Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. BMC Endocr Disord 2019;19:87. [PMID: 31438915 DOI: 10.1186/s12902-019-0412-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
71 Salukhov VV, Romashevsky BV. Modern aspects for preventive therapy of type 2 diabetes mellitus. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-4-6-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Xiong XL, Zhang RX, Bi Y, Zhou WH, Yu Y, Zhu DL. Machine Learning Models in Type 2 Diabetes Risk Prediction: Results from a Cross-sectional Retrospective Study in Chinese Adults. Curr Med Sci 2019;39:582-8. [PMID: 31346994 DOI: 10.1007/s11596-019-2077-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
73 Shaw JE. Prediabetes: lifestyle, pharmacotherapy or regulation? Ther Adv Endocrinol Metab 2019;10:2042018819863020. [PMID: 31321022 DOI: 10.1177/2042018819863020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
74 Sheng Z, Cao JY, Pang YC, Xu HC, Chen JW, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J. Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:455. [PMID: 31354627 DOI: 10.3389/fendo.2019.00455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
75 Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, Knowler WC, Mather KJ, Mudaliar S, Orchard TJ, Temprosa M, White NH; Research Group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 2019;62:1319-28. [PMID: 31270584 DOI: 10.1007/s00125-019-4928-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
76 Ha J, Sherman A. Type 2 Diabetes: One Disease, Many Pathways.. [DOI: 10.1101/648816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Bonaventura A, Montecucco F. The STOP DIABETES study: when prevention works. Acta Diabetol 2019;56:501-4. [PMID: 30826915 DOI: 10.1007/s00592-019-01309-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Barengo NC, Acosta T, Arrieta A, Ricaurte C, Smits D, Florez K, Tuomilehto JO. Early Lifestyle Interventions in People with Impaired Glucose Tolerance in Northern Colombia: The DEMOJUAN Project. Int J Environ Res Public Health 2019;16:E1403. [PMID: 31003515 DOI: 10.3390/ijerph16081403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
79 Yoon SY, Lee SR, Hwang JY, Benndorf R, Beemelmanns C, Chung SJ, Kim KH. Fridamycin A, a Microbial Natural Product, Stimulates Glucose Uptake without Inducing Adipogenesis. Nutrients 2019;11:E765. [PMID: 30939853 DOI: 10.3390/nu11040765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
80 Palazzuoli A, Ceccarelli E, Ruocco G, Nuti R. Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev 2018;23:325-35. [PMID: 29359260 DOI: 10.1007/s10741-018-9669-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
81 Brannick B, Dagogo-Jack S. Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. Endocrinol Metab Clin North Am 2018;47:33-50. [PMID: 29407055 DOI: 10.1016/j.ecl.2017.10.001] [Cited by in Crossref: 91] [Cited by in F6Publishing: 105] [Article Influence: 30.3] [Reference Citation Analysis]
82 Twickler MTB, Regieli J, Grobben R, Hart EA, Tesselaar ME, Meijer RCA, Chamuleau SAJ, Nathoe HM. Impact of Endocrine Disorders on the Heart. Endocrinology 2019. [DOI: 10.1007/978-3-319-66362-3_3-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Distefano JK, Watanabe RM. Pharmacoepigenetics in Type 2 Diabetes Mellitus. Pharmacoepigenetics 2019. [DOI: 10.1016/b978-0-12-813939-4.00018-8] [Reference Citation Analysis]
84 Cook CB, Chakkera H. Diabetes Mellitus and Renal Transplantation. Endocrine Disorders in Kidney Disease 2019. [DOI: 10.1007/978-3-319-97765-2_6] [Reference Citation Analysis]
85 Fagg J, Valabhji J. How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing? Diabet Med 2019;36:316-25. [PMID: 30466172 DOI: 10.1111/dme.13867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
86 American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S29-33. [PMID: 30559229 DOI: 10.2337/dc19-S003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 22.8] [Reference Citation Analysis]
87 Kubota K, Kamijima Y, Kao Yang YH, Kimura S, Chia-Cheng Lai E, Man KKC, Ryan P, Schuemie M, Stang P, Su CC, Wong ICK, Zhang Y, Setoguchi S. Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study. PLoS One 2018;13:e0208796. [PMID: 30540837 DOI: 10.1371/journal.pone.0208796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
88 Rhee SY, Chon S, Ahn KJ, Woo JT; Korean Diabetes Prevention Study Investigators. Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. Diabetes Metab J 2019;43:49-58. [PMID: 30398039 DOI: 10.4093/dmj.2018.0033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
89 Wallner M, Eaton DM, von Lewinski D, Sourij H. Revisiting the Diabetes-Heart Failure Connection. Curr Diab Rep 2018;18:134. [PMID: 30343339 DOI: 10.1007/s11892-018-1116-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
90 Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium., RISE Collaborators. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care 2018;41:2544-51. [PMID: 30282699 DOI: 10.2337/dc18-1662] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
91 Echouffo-Tcheugui JB, Kengne AP, Ali MK. Issues in Defining the Burden of Prediabetes Globally. Curr Diab Rep 2018;18:105. [PMID: 30229351 DOI: 10.1007/s11892-018-1089-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
92 Tong YZ, Tong NW, Teng WP, Mu YM, Zhao JJ, Shan ZY, Ning G; Chinese Society of Endocrinology. Consensus on the Prevention of Type 2 Diabetes in Chinese Adults. Chin Med J (Engl) 2017;130:600-6. [PMID: 28229993 DOI: 10.4103/0366-6999.200532] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
93 Luk AOY, Zee BCY, Chong M, Ozaki R, Rausch CW, Chan MHM, Ma RCW, Kong APS, Chow FCC, Chan JCN. A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes. BMC Endocr Disord 2018;18:59. [PMID: 30170579 DOI: 10.1186/s12902-018-0288-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Bowes CD, Lien LF, Butler J. Treatment of Diabetes in Patients with Heart Failure. Curr Cardiol Rep 2018;20:97. [PMID: 30151728 DOI: 10.1007/s11886-018-1032-5] [Reference Citation Analysis]
95 Hong F, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. Int J Mol Sci 2018;19:E2189. [PMID: 30060458 DOI: 10.3390/ijms19082189] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 20.0] [Reference Citation Analysis]
96 LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG; D2d Research Group. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-9. [PMID: 29941495 DOI: 10.2337/dc18-0240] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
97 Vallée A, Lévy BL, Blacher J. Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension. Curr Hypertens Rep 2018;20:62. [PMID: 29884931 DOI: 10.1007/s11906-018-0860-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
98 Jiang L, Wu G, Fang P, Xu Z, Tang Z. Development of clinical risk models for diabetic cardiovascular autonomic neuropathy in a Chinese population using logistic regression analysis. Tradit Med Mod Med 2018;01:137-43. [DOI: 10.1142/s2575900018500076] [Reference Citation Analysis]
99 Juarez LD, Gonzalez JS, Agne AA, Kulczycki A, Pavela G, Carson AP, Shelley JP, Cherrington AL. Diabetes risk scores for Hispanics living in the United States: A systematic review. Diabetes Res Clin Pract 2018;142:120-9. [PMID: 29852236 DOI: 10.1016/j.diabres.2018.05.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Phua WWT, Wong MXY, Liao Z, Tan NS. An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors. Int J Mol Sci 2018;19:E1425. [PMID: 29747466 DOI: 10.3390/ijms19051425] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
101 Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group. Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. Am Heart J 2018;199:170-5. [PMID: 29754657 DOI: 10.1016/j.ahj.2017.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Ayabe T, Ohya R, Kondo K, Ano Y. Iso-α-acids, bitter components of beer, prevent obesity-induced cognitive decline. Sci Rep 2018;8:4760. [PMID: 29555941 DOI: 10.1038/s41598-018-23213-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
103 Kiss R, Szabó K, Gesztelyi R, Somodi S, Kovács P, Szabó Z, Németh J, Priksz D, Kurucz A, Juhász B, Szilvássy Z. Insulin-Sensitizer Effects of Fenugreek Seeds in Parallel with Changes in Plasma MCH Levels in Healthy Volunteers. Int J Mol Sci 2018;19:E771. [PMID: 29518003 DOI: 10.3390/ijms19030771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
104 Sangle GV, Patil M, Deshmukh NJ, Shengule SA, Kamble S, Vuppalavanchu KK, Kale S, Baig MLA, Singh G, Shaikh J, Tripathi J, Aravindababu P. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. Eur J Clin Pharmacol 2018;74:561-9. [PMID: 29511780 DOI: 10.1007/s00228-018-2433-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 Chatterjee S, Davies M, Khunti K. Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. Am J Cardiovasc Drugs 2018;18:13-24. [PMID: 28762143 DOI: 10.1007/s40256-017-0239-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
106 Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, Zhu D, Chen L, Chen L, Guo L, Guo X, Ji Q, Li Q, Li X, Liu J, Ran X, Shan Z, Shi L, Song G, Yang L, Yang Y, Yang W; Chinese Diabetes Society. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev 2016;32:442-58. [PMID: 27464265 DOI: 10.1002/dmrr.2827] [Cited by in Crossref: 187] [Cited by in F6Publishing: 204] [Article Influence: 46.8] [Reference Citation Analysis]
107 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_16-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Watanabe RM. Physiologic Interpretation of GWAS Signals for Type 2 Diabetes. Methods in Molecular Biology 2018. [DOI: 10.1007/978-1-4939-7471-9_18] [Reference Citation Analysis]
109 Perreault L. Prevention of Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_2] [Reference Citation Analysis]
110 Hong SW, Lee J, Cho JH, Kwon H, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Pioglitazone Attenuates Palmitate-Induced Inflammation and Endoplasmic Reticulum Stress in Pancreatic β-Cells. Endocrinol Metab (Seoul) 2018;33:105-13. [PMID: 29589392 DOI: 10.3803/EnM.2018.33.1.105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
111 Joung H, Kwon H. Pharmacological Intervention for the Prevention of Diabetes Mellitus. J Korean Diabetes 2018;19:140. [DOI: 10.4093/jkd.2018.19.3.140] [Reference Citation Analysis]
112 Mechanick JI, Divisions of Cardiology and Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York City, NY, US. Dysglycemia-based Chronic Disease—Diabetes Re-worked. US Endocrinology 2018;14:77. [DOI: 10.17925/use.2018.14.2.77] [Reference Citation Analysis]
113 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_16] [Reference Citation Analysis]
114 Knutson KL, Wu D, Patel SR, Loredo JS, Redline S, Cai J, Gallo LC, Mossavar-Rahmani Y, Ramos AR, Teng Y, Daviglus ML, Zee PC. Association Between Sleep Timing, Obesity, Diabetes: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Cohort Study. Sleep 2017;40. [PMID: 28329091 DOI: 10.1093/sleep/zsx014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 10.6] [Reference Citation Analysis]
115 Kukhtar D, Mulero M, Beltrán-debón R, Valls C, Pujadas G, Garcia-vallve S. Multiple Peroxisome Proliferator-Activated Receptor-Based Ligands. Methods and Principles in Medicinal Chemistry 2017. [DOI: 10.1002/9783527674381.ch14] [Reference Citation Analysis]
116 Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177:1808-17. [PMID: 29114778 DOI: 10.1001/jamainternmed.2017.6040] [Cited by in Crossref: 167] [Cited by in F6Publishing: 173] [Article Influence: 33.4] [Reference Citation Analysis]
117 Wen J, Hao J, Liang Y, Li S, Cao K, Lu X, Lu X, Wang N. A non-invasive risk score for predicting incident diabetes among rural Chinese people: A village-based cohort study. PLoS One 2017;12:e0186172. [PMID: 29095851 DOI: 10.1371/journal.pone.0186172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
118 Yang W, Li Y, Tian T, Wang L, Lee P, Hua Q. Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications. BMC Endocr Disord 2017;17:67. [PMID: 29065866 DOI: 10.1186/s12902-017-0216-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
119 Uryas’ev OM, Morgunova ZA, Gorbunova DY, Shcherbakova ON, Pyko AA. Modern aspects of the treatment and prevention of diabetes type 2 in patients with metabolic syndrome. Kazan Med J 2017;98:770-774. [DOI: 10.17750/kmj2017-770] [Reference Citation Analysis]
120 Pang B, Zhang Y, Liu J, He LS, Zheng YJ, Lian FM, Tong XL. Prevention of Type 2 Diabetes with the Chinese Herbal Medicine Tianqi Capsule: A Systematic Review and Meta-Analysis. Diabetes Ther 2017;8:1227-42. [PMID: 29027648 DOI: 10.1007/s13300-017-0316-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
121 Herman WH. The global agenda for the prevention of type 2 diabetes. Nutr Rev 2017;75:13-8. [PMID: 28049746 DOI: 10.1093/nutrit/nuw034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
122 Webb R, Hughes MG, Thomas AW, Morris K. The Ability of Exercise-Associated Oxidative Stress to Trigger Redox-Sensitive Signalling Responses. Antioxidants (Basel) 2017;6:E63. [PMID: 28796154 DOI: 10.3390/antiox6030063] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
123 Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017;60:1601-11. [PMID: 28770322 DOI: 10.1007/s00125-017-4361-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
124 Zeng H, Tong R, Tong W, Yang Q, Qiu M, Xiong A, Sun S, Ding L, Zhang H, Yang L, Tian J. Metabolic Biomarkers for Prognostic Prediction of Pre-diabetes: results from a longitudinal cohort study. Sci Rep 2017;7:6575. [PMID: 28747646 DOI: 10.1038/s41598-017-06309-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
125 Patel PA, Liang L, Khazanie P, Hammill BG, Fonarow GC, Yancy CW, Bhatt DL, Curtis LH, Hernandez AF. Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circ Heart Fail 2016;9:e002638. [PMID: 27413035 DOI: 10.1161/CIRCHEARTFAILURE.115.002638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
126 Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes 2017; 8(6): 270-277 [PMID: 28694927 DOI: 10.4239/wjd.v8.i6.270] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016;241:1323-31. [PMID: 27302176 DOI: 10.1177/1535370216654227] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
128 Oyama MA, Ellenberg SS, Shaw PA. Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. J Vet Intern Med 2017;31:970-8. [PMID: 28557000 DOI: 10.1111/jvim.14744] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
129 Perdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovasc Endocrinol 2017;6:55-61. [PMID: 31646121 DOI: 10.1097/XCE.0000000000000110] [Reference Citation Analysis]
130 Hu Z, Qin L, Xu H. One-Year Results of a Synthetic Intervention Model for the Primary Prevention of T2D among Elderly Individuals with Prediabetes in Rural China. Int J Environ Res Public Health 2017;14:E417. [PMID: 28420105 DOI: 10.3390/ijerph14040417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
131 Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials 2017;18:122. [PMID: 28288676 DOI: 10.1186/s13063-017-1870-2] [Cited by in Crossref: 155] [Cited by in F6Publishing: 166] [Article Influence: 31.0] [Reference Citation Analysis]
132 Shi YL, Liu WJ, Zhang XF, Su WJ, Chen NN, Lu SH, Wang LY, Shi XL, Li ZB, Yang SY. Effect of Chinese Herbal Medicine Jinlida Granule in Treatment of Patients with Impaired Glucose Tolerance. Chin Med J (Engl) 2016;129:2281-6. [PMID: 27647185 DOI: 10.4103/0366-6999.190676] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
133 Krentz AJ, Scuteri A. Insulin resistance and the metabolic syndrome. Diabetes in Old Age 2017. [DOI: 10.1002/9781118954621.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Horton ES. Preventative strategies. Diabetes in Old Age 2017. [DOI: 10.1002/9781118954621.ch3] [Reference Citation Analysis]
135 Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol. 2017;16:18. [PMID: 28148253 DOI: 10.1186/s12933-017-0499-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
136 Dunbar JA. Diabetes Prevention in Australia: 10 Years Results and Experience. Diabetes Metab J 2017;41:160-7. [PMID: 28537055 DOI: 10.4093/dmj.2017.41.3.160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
137 Chandra M, Miriyala S, Panchatcharam M. PPARγ and Its Role in Cardiovascular Diseases. PPAR Res 2017;2017:6404638. [PMID: 28243251 DOI: 10.1155/2017/6404638] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
138 Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. J Am Heart Assoc 2017;6:e003892. [PMID: 28087508 DOI: 10.1161/JAHA.116.003892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
139 Luo Y, Paul SK, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Wang H. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. J Diabetes Res 2017;2017:7602408. [PMID: 28168204 DOI: 10.1155/2017/7602408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
140 Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism 2017;70:192-5. [PMID: 28095990 DOI: 10.1016/j.metabol.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
141 Kim NH, Kim SG. Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes. J Korean Diabetes 2017;18:7. [DOI: 10.4093/jkd.2017.18.1.7] [Reference Citation Analysis]
142 Henwood J, Sagner M, Rössner S, Binns A. Pharmakotherapie und Medikamente. Präventionsmedizin 2017. [DOI: 10.1016/b978-3-437-23274-9.00024-1] [Reference Citation Analysis]
143 Kalin MF, Goncalves M, John-kalarickal J, Fonseca V. Pathogenesis of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_13] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
144 Rauch G, Schüler S, Kieser M. Clinical Trial Examples with (Composite) Time-to-Event Endpoints. Springer Series in Pharmaceutical Statistics 2017. [DOI: 10.1007/978-3-319-73770-6_20] [Reference Citation Analysis]
145 Dagogo-jack S. Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. Diabetes Mellitus in Developing Countries and Underserved Communities 2017. [DOI: 10.1007/978-3-319-41559-8_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
146 Kalin MF, Goncalves M, John-kalarickal J, Fonseca V. Pathogenesis of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-20797-1_13-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Rauch G, Schüler S, Kieser M. Challenges of Composite Endpoints. Springer Series in Pharmaceutical Statistics 2017. [DOI: 10.1007/978-3-319-73770-6_2] [Reference Citation Analysis]
148 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_50] [Reference Citation Analysis]
149 Rauch G, Schüler S, Kieser M. Clinical Trial Examples. Springer Series in Pharmaceutical Statistics 2017. [DOI: 10.1007/978-3-319-73770-6_4] [Reference Citation Analysis]
150 Bray GA. Obesity and the Risk for Type 2 Diabetes. Nutrition in the Prevention and Treatment of Disease 2017. [DOI: 10.1016/b978-0-12-802928-2.00030-8] [Reference Citation Analysis]
151 Henwood J, Rössner S, Binns A. Medicines. Lifestyle Medicine 2017. [DOI: 10.1016/b978-0-12-810401-9.00024-3] [Reference Citation Analysis]
152 Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, Ichise M, Manly J, Devanand DP, Bagiella E. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. J Alzheimers Dis 2016;51:501-14. [PMID: 26890736 DOI: 10.3233/JAD-150493] [Cited by in Crossref: 134] [Cited by in F6Publishing: 138] [Article Influence: 22.3] [Reference Citation Analysis]
153 Kondo S, Suzuki A, Kurokawa M, Hasumi K. Intake of kale suppresses postprandial increases in plasma glucose: A randomized, double-blind, placebo-controlled, crossover study. Biomed Rep 2016;5:553-8. [PMID: 27882216 DOI: 10.3892/br.2016.767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
154 Fizelova M, Jauhiainen R, Stančáková A, Kuusisto J, Laakso M. Finnish Diabetes Risk Score Is Associated with Impaired Insulin Secretion and Insulin Sensitivity, Drug-Treated Hypertension and Cardiovascular Disease: A Follow-Up Study of the METSIM Cohort. PLoS One 2016;11:e0166584. [PMID: 27851812 DOI: 10.1371/journal.pone.0166584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
155 Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, Eicher JD, Sharp SJ, Luan J, De Lucia Rolfe E, Stewart ID, Wheeler E, Willems SM, Adams C, Yaghootkar H, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, Langenberg C, O'Rahilly S, Scott RA; EPIC-InterAct Consortium., Cambridge FPLD1 Consortium. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 2017;49:17-26. [PMID: 27841877 DOI: 10.1038/ng.3714] [Cited by in Crossref: 338] [Cited by in F6Publishing: 346] [Article Influence: 56.3] [Reference Citation Analysis]
156 Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr) 2016;38:485-93. [PMID: 27585671 DOI: 10.1007/s11357-016-9946-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
157 Naidoo P, Wing J, Rambiritch V. Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. JMIR Res Protoc 2016;5:e145. [PMID: 27491324 DOI: 10.2196/resprot.5073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
158 Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-92. [PMID: 27465265 DOI: 10.2337/dc16-0798] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
159 Kabade DM, Koppad A, Khatawkar A, Kabade SD, Ahmed A. ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS. jebmh 2016;3:2272-2282. [DOI: 10.18410/jebmh/2016/503] [Reference Citation Analysis]
160 Song X, Qiu M, Zhang X, Wang H, Tong W, Ju L, Gu L, Sun S, Zhang H, Wang W, Tian J. Gender-related affecting factors of prediabetes on its 10-year outcome. BMJ Open Diabetes Res Care. 2016;4:e000169. [PMID: 27239315 DOI: 10.1136/bmjdrc-2015-000169] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
161 Guo VY, Yu EY, Wong CKh, Sit RW, Wang JH, Ho SY, Lam CL. Validation of a nomogram for predicting regression from impaired fasting glucose to normoglycaemia to facilitate clinical decision making. Fam Pract 2016;33:401-7. [PMID: 27142313 DOI: 10.1093/fampra/cmw031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
162 Naik D, Thomas N. Yoga- a potential solution for diabetes & metabolic syndrome. Indian J Med Res 2015;141:753-6. [PMID: 26205017 DOI: 10.4103/0971-5916.160689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
163 Zhang M, Zhang H, Wang C, Ren Y, Wang B, Zhang L, Yang X, Zhao Y, Han C, Pang C, Yin L, Xue Y, Zhao J, Hu D. Development and Validation of a Risk-Score Model for Type 2 Diabetes: A Cohort Study of a Rural Adult Chinese Population. PLoS One 2016;11:e0152054. [PMID: 27070555 DOI: 10.1371/journal.pone.0152054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
164 Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs 2015;75:1071-94. [PMID: 26059289 DOI: 10.1007/s40265-015-0416-8] [Cited by in Crossref: 143] [Cited by in F6Publishing: 109] [Article Influence: 23.8] [Reference Citation Analysis]
165 Patel PA, Scott CG, Rodeheffer RJ, Chen HH. The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clin Proc 2016;91:623-33. [PMID: 27063063 DOI: 10.1016/j.mayocp.2016.02.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
166 Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016;101:2056-2062. [PMID: 26982008 DOI: 10.1210/jc.2015-4202] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
167 Hanefeld M, Monnier L, Schnell O, Owens D. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther 2016;7:187-201. [DOI: 10.1007/s13300-016-0153-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
168 Hsu JJ, Fonarow GC. Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses? Curr Cardiovasc Risk Rep 2016;10. [DOI: 10.1007/s12170-016-0486-5] [Reference Citation Analysis]
169 Vidal J, Jiménez A. Definition, History, and Management of the Metabolic Syndrome and Management Gaps. Metabolic Syndrome and Diabetes 2016. [DOI: 10.1007/978-1-4939-3220-7_1] [Reference Citation Analysis]
170 Kalin MF, Goncalves M, Fonseca V. Pathogenesis of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2016. [DOI: 10.1007/978-3-319-20797-1_13-1] [Reference Citation Analysis]
171 Yan Q, Li X, Feng B. The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP). BMC Endocr Disord 2015;15:74. [PMID: 26626301 DOI: 10.1186/s12902-015-0071-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
172 Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, Shibao CA. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. J Clin Endocrinol Metab 2015;100:4533-40. [PMID: 26580240 DOI: 10.1210/jc.2015-3415] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
173 Klein MS, Shearer J. Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application. J Diabetes Res 2016;2016:3898502. [PMID: 26636104 DOI: 10.1155/2016/3898502] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 11.3] [Reference Citation Analysis]
174 Stempa O. Pioglitazone: lessons and learnings 15 years since launch and beyond. Diabetes Management 2015;5:415-429. [DOI: 10.2217/dmt.15.38] [Reference Citation Analysis]
175 Huang J, Ou HY, Lin J, Karnchanasorn R, Feng W, Samoa R, Chuang LM, Chiu KC. The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination. PLoS One 2015;10:e0139730. [PMID: 26509504 DOI: 10.1371/journal.pone.0139730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
176 Lee WS, Kim J. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Res 2015;2015:271983. [PMID: 26587015 DOI: 10.1155/2015/271983] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
177 Courtney MR, Moler EJ, Osborne JA, Whitney G, Conard SE. An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes Metab Syndr Obes 2015;8:447-53. [PMID: 26425102 DOI: 10.2147/DMSO.S78810] [Reference Citation Analysis]
178 Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
179 Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stévant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clément K, Rizkalla SW. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One 2015;10:e0138646. [PMID: 26406981 DOI: 10.1371/journal.pone.0138646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
180 Wang P, Huang R, Lu S, Xia W, Sun H, Sun J, Cai R, Wang S. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol 2015;14:124. [PMID: 26392171 DOI: 10.1186/s12933-015-0285-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
181 Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Curr Ther Res Clin Exp 2015;77:83-9. [PMID: 26543510 DOI: 10.1016/j.curtheres.2015.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
182 Osei E, Fonville S, Zandbergen AA, Brouwers PJ, Mulder LJ, Lingsma HF, Dippel DW, Koudstaal PJ, den Hertog HM. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. Trials 2015;16:332. [PMID: 26242578 DOI: 10.1186/s13063-015-0882-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
183 Holt RI. The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015;132:86-96. [PMID: 25976975 DOI: 10.1111/acps.12443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
184 Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 2015;58:2336-43. [PMID: 26197707 DOI: 10.1007/s00125-015-3689-2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
185 Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 2015;17:1033-41. [PMID: 26094974 DOI: 10.1111/dom.12507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
186 Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015;98:145-61. [PMID: 25963811 DOI: 10.1002/cpt.143] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
187 Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia. 2015;58:2238-2246. [PMID: 26109213 DOI: 10.1007/s00125-015-3660-2] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 12.0] [Reference Citation Analysis]
188 Srinivasan S, Florez JC. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther 2015;98:162-9. [PMID: 25974616 DOI: 10.1002/cpt.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
189 Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-76. [PMID: 25249668 DOI: 10.2337/dc14-0817] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
190 Garretson JT, Teubner BJ, Grove KL, Vazdarjanova A, Ryu V, Bartness TJ. Peroxisome proliferator-activated receptor γ controls ingestive behavior, agouti-related protein, and neuropeptide Y mRNA in the arcuate hypothalamus. J Neurosci 2015;35:4571-81. [PMID: 25788674 DOI: 10.1523/JNEUROSCI.2129-14.2015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
191 Monami M, Mannucci E. Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes? Curr Cardiovasc Risk Rep 2015;9. [DOI: 10.1007/s12170-015-0465-2] [Reference Citation Analysis]
192 Trivin C, Metzger M, Haymann JP, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Stengel B, Thervet E; NephroTest Study Group. Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD. Clin J Am Soc Nephrol 2015;10:957-64. [PMID: 25979978 DOI: 10.2215/CJN.08540814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
193 Yajnik CS, Katre PA, Joshi SM, Kumaran K, Bhat DS, Lubree HG, Memane N, Kinare AS, Pandit AN, Bhave SA, Bavdekar A, Fall CH. Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune Children's Study. Diabetologia 2015;58:1626-36. [PMID: 25940643 DOI: 10.1007/s00125-015-3602-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
194 Apostoli AJ, Roche JM, Schneider MM, SenGupta SK, Di Lena MA, Rubino RE, Peterson NT, Nicol CJ. Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression. Mol Cancer 2015;14:85. [PMID: 25889730 DOI: 10.1186/s12943-015-0347-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
195 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 242] [Cited by in F6Publishing: 256] [Article Influence: 34.6] [Reference Citation Analysis]
196 Kumar A, Shiloach J, Betenbaugh MJ, Gallagher EJ. The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice. Nutr Metab (Lond) 2015;12:8. [PMID: 25784953 DOI: 10.1186/s12986-015-0003-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
197 Abdul-ghani M, Defronzo RA, Eldor R. Combination therapy in type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch46] [Reference Citation Analysis]
198 Mudaliar S, Henry RR. PPAR agonists in the treatment of diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch44] [Reference Citation Analysis]
199 Yates T, Davies MJ. Prevention of type 2 diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch38] [Reference Citation Analysis]
200 Mata-Cases M, Artola S, Escalada J, Ezkurra-Loyola P, Ferrer-García JC, Fornos JA, Girbés J, Rica I; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. Aten Primaria 2015;47:456-68. [PMID: 25735589 DOI: 10.1016/j.aprim.2014.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
201 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. Revista Clínica Española (English Edition) 2015;215:117-29. [DOI: 10.1016/j.rceng.2014.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
202 Nakatsu D, Horiuchi Y, Kano F, Noguchi Y, Sugawara T, Takamoto I, Kubota N, Kadowaki T, Murata M. L-cysteine reversibly inhibits glucose-induced biphasic insulin secretion and ATP production by inactivating PKM2. Proc Natl Acad Sci USA. 2015;112:E1067-E1076. [PMID: 25713368 DOI: 10.1073/pnas.1417197112] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
203 Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes 2015; 6(1): 109-124 [PMID: 25685282 DOI: 10.4239/wjd.v6.i1.109] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 125] [Article Influence: 17.1] [Reference Citation Analysis]
204 Iraj B, Salami R, Feizi A, Amini M. The profile of hypertension and dyslipidemia in prediabetic subjects; results of the Isfahan Diabetes Prevention program: A large population-based study. Adv Biomed Res 2015;4:27. [PMID: 25709992 DOI: 10.4103/2277-9175.150415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
205 Pointer MA, Hicks K, Williams-Devane C, Wells C, Greene N. Gender differences in preclinical markers of kidney injury in a rural north Carolina african-american cohort. Front Public Health 2015;3:7. [PMID: 25674558 DOI: 10.3389/fpubh.2015.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab 2015;100:1855-62. [PMID: 25603459 DOI: 10.1210/jc.2014-3824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
207 Paolini P, Pick D, Lapira J, Sannino G, Pasqualini L, Ludka C, Sprague LJ, Zhang X, Bartolotta EA, Vazquez-Hidalgo E, Barba DT, Bazan C, Hardiman G. Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. Pharmacogenomics 2014;15:759-74. [PMID: 24897284 DOI: 10.2217/pgs.14.39] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
208 Færch K, Vistisen D, Johansen NB, Jørgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep 2014;14:493. [PMID: 24743942 DOI: 10.1007/s11892-014-0493-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
209 Coolsen MM, Clermonts SH, van Dam RM, Winkens B, Malagó M, Fusai GK, Dejong CH, Olde Damink SW. Development of a composite endpoint for randomized controlled trials in pancreaticoduodenectomy. World J Surg 2014;38:1468-75. [PMID: 24366279 DOI: 10.1007/s00268-013-2421-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
210 Ajala O, English P. Dietary Management of Pre-Diabetes and Type 2 Diabetes. Glucose Intake and Utilization in Pre-Diabetes and Diabetes 2015. [DOI: 10.1016/b978-0-12-800093-9.00007-7] [Reference Citation Analysis]
211 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2015. [DOI: 10.1007/978-3-319-20797-1_50-1] [Reference Citation Analysis]
212 Ríos J, Andújar I. Lanostanoids from Fungi as Potential Medicinal Agents. Fungal Metabolites 2015. [DOI: 10.1007/978-3-319-19456-1_19-1] [Reference Citation Analysis]
213 Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep. 2014;16:476. [PMID: 24643902 DOI: 10.1007/s11886-014-0476-5] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 7.8] [Reference Citation Analysis]
214 Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev 2014;10:2-42. [PMID: 24524730 DOI: 10.2174/1573399810666140214093600] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
215 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig 2015;6:309-16. [PMID: 25969716 DOI: 10.1111/jdi.12290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
216 Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes. Nat Rev Endocrinol 2015;11:90-100. [PMID: 25365922 DOI: 10.1038/nrendo.2014.185] [Cited by in Crossref: 269] [Cited by in F6Publishing: 282] [Article Influence: 33.6] [Reference Citation Analysis]
217 Sénéchal M, Slaght J, Bharti N, Bouchard DR. Independent and combined effect of diet and exercise in adults with prediabetes. Diabetes Metab Syndr Obes 2014;7:521-9. [PMID: 25382981 DOI: 10.2147/DMSO.S62367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
218 Sawhney A, Rothkopf M. Metabolic Syndrome. Metabolic Medicine and Surgery 2014. [DOI: 10.1201/b17616-7] [Reference Citation Analysis]
219 Alyass A, Almgren P, Akerlund M, Dushoff J, Isomaa B, Nilsson P, Tuomi T, Lyssenko V, Groop L, Meyre D. Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia. 2015;58:87-97. [PMID: 25292440 DOI: 10.1007/s00125-014-3390-x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 11.3] [Reference Citation Analysis]
220 Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi CA, Crandall J, Florez JC, Fowler S, Goldberg R, Kahn SE, Knowler WC, Lachin JM, Murphy MB, Venditti E; Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes 2015;64:989-98. [PMID: 25277389 DOI: 10.2337/db14-0333] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
221 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91. [PMID: 25242225 DOI: 10.1016/j.cmet.2014.08.005] [Cited by in Crossref: 312] [Cited by in F6Publishing: 322] [Article Influence: 39.0] [Reference Citation Analysis]
222 Stulnig T. Insulintherapie bei Typ-2-Diabetes mellitus. Diabetologe 2014;10:460-465. [DOI: 10.1007/s11428-013-1151-y] [Reference Citation Analysis]
223 Glauber H, Karnieli E. Preventing type 2 diabetes mellitus: a call for personalized intervention. Perm J 2013;17:74-9. [PMID: 24355893 DOI: 10.7812/TPP/12-143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
224 Leiva E, Mujica V, Orrego R, Wehinger S, Soto A, Icaza G, Vásquez M, Díaz L, Andrews M, Arredondo M. Subjects with impaired fasting glucose: evolution in a period of 6 years. J Diabetes Res 2014;2014:710370. [PMID: 25215305 DOI: 10.1155/2014/710370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
225 Saisho Y. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med 2014;3:923-43. [PMID: 26237486 DOI: 10.3390/jcm3030923] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
226 Qin G, Lu L, Xiao Y, Zhu Y, Pan W, Xu X, Shen S, Das UN. A cross-sectional study of the relationship between serum liver enzymes level and the incidence of impaired fasting glucose in males and females. Med Sci Monit 2014;20:1319-25. [PMID: 25066107 DOI: 10.12659/MSM.890698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
227 Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ 2014;349:g4485. [PMID: 25028385 DOI: 10.1136/bmj.g4485] [Cited by in Crossref: 131] [Cited by in F6Publishing: 144] [Article Influence: 16.4] [Reference Citation Analysis]
228 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd009989.pub2] [Reference Citation Analysis]
229 Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC; ACCORD Group of Investigators. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia 2014;57:2030-7. [PMID: 24985147 DOI: 10.1007/s00125-014-3318-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
230 Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014;37:2622-2631. [PMID: 24969574 DOI: 10.2337/dc14-0656] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
231 Lu Y, Ma D, Xu W, Shao S, Yu X. Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig 2015;6:78-86. [PMID: 25621136 DOI: 10.1111/jdi.12246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
232 Verschuren L, Wielinga PY, Kelder T, Radonjic M, Salic K, Kleemann R, van Ommen B, Kooistra T. A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC Med Genomics 2014;7:35. [PMID: 24938300 DOI: 10.1186/1755-8794-7-35] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
233 Hwee J, Cauch-Dudek K, Victor JC, Ng R, Shah BR. Utilization of Diabetes Education Centres in Ontario by people without diabetes. Can J Diabetes 2014;38:186-90. [PMID: 24909089 DOI: 10.1016/j.jcjd.2013.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
234 Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L, Chasman DI, Yusuf S, Paré G. Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J 2014;35:2242-8a. [PMID: 24796340 DOI: 10.1093/eurheartj/ehu168] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
235 DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138. [PMID: 23882037 DOI: 10.2337/dcs13-2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 187] [Article Influence: 21.4] [Reference Citation Analysis]
236 Mancia G, Grassi G. Individualization of antihypertensive drug treatment. Diabetes Care 2013;36 Suppl 2:S301-6. [PMID: 23882063 DOI: 10.2337/dcS13-2013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
237 Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36 Suppl 2:S162-74. [PMID: 23882042 DOI: 10.2337/dcS13-2003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 9.1] [Reference Citation Analysis]
238 Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med 2014;31:1064-8. [PMID: 24646311 DOI: 10.1111/dme.12437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
239 Schubert C, Hsia J. The Cardiovascular Spectrum of Adverse Drug Reactions. Mann's Pharmacovigilance 2014. [DOI: 10.1002/9781118820186.ch38] [Reference Citation Analysis]
240 Yu X, Chen P, Wang H, Jin H, Jia W, Wang L. Clinical study of exercise on improvement of β-cell function and insulin resistance in non-diabetic young offsprings of diabetic patients. J Endocrinol Invest 2014;37:353-8. [PMID: 24682911 DOI: 10.1007/s40618-013-0033-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
242 Dyson PA. Addressing noncommunicable disease at the population level: a focus on diabetes. Diabetes Management 2014;4:153-163. [DOI: 10.2217/dmt.13.75] [Reference Citation Analysis]
243 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013;19:536-557. [PMID: 23816937 DOI: 10.4158/ep13176.cs] [Cited by in Crossref: 148] [Cited by in F6Publishing: 193] [Article Influence: 18.5] [Reference Citation Analysis]
244 Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014;12:258-268. [PMID: 24512556 DOI: 10.1089/met.2013.0128] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 9.1] [Reference Citation Analysis]
245 Knowler WC, Ackermann RT. Preventing diabetes in American Indian communities. Diabetes Care 2013;36:1820-2. [PMID: 23801794 DOI: 10.2337/dc12-2635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
246 Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329-341. [PMID: 23625197 DOI: 10.1007/s11892-013-0378-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
247 Ganne S, Arora S, Karam J, Mcfarlane SI. Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. Expert Review of Cardiovascular Therapy 2014;5:201-11. [DOI: 10.1586/14779072.5.2.201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
248 Hoekman J, Lambers Heerspink HJ, Viberti G, Green D, Mann JF, de Zeeuw D. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clin J Am Soc Nephrol 2014;9:490-8. [PMID: 24408122 DOI: 10.2215/CJN.07040713] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
249 Lakhdar AF. Weight Gain on Glucose-Lowering Agents. Controversies in Obesity 2014. [DOI: 10.1007/978-1-4471-2834-2_32] [Reference Citation Analysis]
250 Genuth SM. How does pioglitazone prevent progression of impaired glucose tolerance to diabetes? Diabetes 2013;62:3663-5. [PMID: 24158994 DOI: 10.2337/db13-1175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
251 Bailey SD, Xie C, Paré G, Montpetit A, Mohan V, Yusuf S, Gerstein H, Engert JC, Anand SS; EpiDREAM and INTERHEART Investigators. Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. Diabetologia 2014;57:738-45. [PMID: 24362726 DOI: 10.1007/s00125-013-3142-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
252 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068-1083. [PMID: 24315620 DOI: 10.1016/s0140-6736(13)62154-6] [Cited by in Crossref: 942] [Cited by in F6Publishing: 990] [Article Influence: 104.7] [Reference Citation Analysis]
253 Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36:1406-1412. [PMID: 23613600 DOI: 10.2337/dc12-2067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
254 Unnikrishnan AG, Bhattacharyya A, Baruah MP, Sinha B, Dharmalingam M, Rao PV. Importance of achieving the composite endpoints in diabetes. Indian J Endocrinol Metab 2013;17:835-43. [PMID: 24083164 DOI: 10.4103/2230-8210.117225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
255 Phillips CM, Kearney PM, McCarthy VJ, Harrington JM, Fitzgerald AP, Perry IJ. Comparison of diabetes risk score estimates and cardiometabolic risk profiles in a middle-aged Irish population. PLoS One 2013;8:e78950. [PMID: 24236074 DOI: 10.1371/journal.pone.0078950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
256 Kovács G, Buday B, Fék A, Literáti-nagy B, Pauer J, Pach P, Vitai M, Péterfai É, Korányi L. Metabolic differences in healthy first-degree female relatives of type 2 diabetic patients. Orvosi Hetilap 2013;154:1747-1753. [DOI: 10.1556/oh.2013.29737] [Reference Citation Analysis]
257 Shih ST, Davis-Lameloise N, Janus ED, Wildey C, Versace VL, Hagger V, Asproloupos D, O'Reilly S, Phillips PA, Ackland M, Skinner T, Oats J, Carter R, Best JD, Dunbar JA; MAGDA Research Group. Mothers After Gestational Diabetes in Australia Diabetes Prevention Program (MAGDA-DPP) post-natal intervention: study protocol for a randomized controlled trial. Trials 2013;14:339. [PMID: 24135085 DOI: 10.1186/1745-6215-14-339] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
258 Ransom T, Goldenberg R, Mikalachki A, Prebtani AP, Punthakee Z. Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S377-S380. [DOI: 10.1016/j.jcjd.2013.07.033] [Reference Citation Analysis]
259 Meneilly GS, Knip A, Tessier D. Le diabète chez les personnes âgées. Canadian Journal of Diabetes 2013;37:S567-S574. [DOI: 10.1016/j.jcjd.2013.07.041] [Reference Citation Analysis]
260 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013;36:3607-3612. [PMID: 24062330 DOI: 10.2337/dc13-0520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
261 Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, SenGupta SK, Nicol CJ. Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer 2014;134:1055-66. [PMID: 23934545 DOI: 10.1002/ijc.28432] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
262 Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A, O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123:4309-4317. [PMID: 24091325 DOI: 10.1172/jci64801] [Cited by in Crossref: 292] [Cited by in F6Publishing: 304] [Article Influence: 32.4] [Reference Citation Analysis]
263 Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252-60. [PMID: 23371283 DOI: 10.1007/s11892-013-0363-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
264 Khavandi K, Amer H, Ibrahim B, Brownrigg J. Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis. 2013;4:242-261. [PMID: 23997928 DOI: 10.1177/2040622313494986] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
265 Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8:e71108. [PMID: 24013136 DOI: 10.1371/journal.pone.0071108] [Cited by in Crossref: 481] [Cited by in F6Publishing: 503] [Article Influence: 53.4] [Reference Citation Analysis]
266 Mannucci E, Monami M, Dicembrini I, Rotella C. The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2013;23:e35-e36. [DOI: 10.1016/j.numecd.2013.02.008] [Reference Citation Analysis]
267 Lopes RD, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Mahaffey KW. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. Am Heart J 2013;166:208-216.e28. [PMID: 23895802 DOI: 10.1016/j.ahj.2013.05.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
268 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920-6. [PMID: 23863810 DOI: 10.2337/db13-0265] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
269 Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS. The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr 2013;5:35. [PMID: 23837919 DOI: 10.1186/1758-5996-5-35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
270 Maria Rotella C, Pala L, Mannucci E. Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab 2013;11:137-44. [PMID: 24348585 DOI: 10.5812/ijem.7551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
271 Jerzak KJ, Pallan S, Gerstein HC. Willingness to take drugs to prevent serious chronic diseases. J Diabetes 2014;6:76-80. [PMID: 23773579 DOI: 10.1111/1753-0407.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol 2013;12 Suppl 1:S3. [PMID: 23819776 DOI: 10.1186/1475-2840-12-S1-S3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
273 Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013;2013:549627. [PMID: 23781121 DOI: 10.1155/2013/549627] [Cited by in Crossref: 207] [Cited by in F6Publishing: 217] [Article Influence: 23.0] [Reference Citation Analysis]
274 Wang Z, Wang J, Chan P. Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs. Evid Based Complement Alternat Med 2013;2013:343594. [PMID: 23737828 DOI: 10.1155/2013/343594] [Cited by in Crossref: 31] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
275 Bachelet VC. A tale of harm, waste and deception: how big pharma has undermined public faith in trial data disclosure and what we can do about it. Medwave 2013;13:e5671-e5671. [DOI: 10.5867/medwave.2013.04.5671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
276 Anand SS, Meyre D, Pare G, Bailey SD, Xie C, Zhang X, Montpetit A, Desai D, Bosch J, Mohan V, Diaz R, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Gaudet D, Gerstein H, Engert JC; EpiDREAM Genetics Investigators. Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. Diabetes Care 2013;36:2836-42. [PMID: 23603917 DOI: 10.2337/dc12-2553] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
277 McEwen LN, Adams SR, Schmittdiel JA, Ferrara A, Selby JV, Herman WH. Screening for impaired fasting glucose and diabetes using available health plan data. J Diabetes Complications 2013;27:580-7. [PMID: 23587840 DOI: 10.1016/j.jdiacomp.2013.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
278 Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226-35. [PMID: 23564296 DOI: 10.1007/s00125-013-2890-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
279 Hu Y, Li L, Ehm MG, Bing N, Song K, Nelson MR, Talmud PJ, Hingorani AD, Kumari M, Kivimäki M, Xu CF, Waterworth DM, Whittaker JC, Abecasis GR, Spino C, Kang HM. The benefits of using genetic information to design prevention trials. Am J Hum Genet 2013;92:547-57. [PMID: 23541341 DOI: 10.1016/j.ajhg.2013.03.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
280 El-Hammady W, Shawky A, El-Annany A. Short term follow-up of prediabetics undergoing elective percutaneous coronary intervention. J Saudi Heart Assoc 2013;25:57-65. [PMID: 24936125 DOI: 10.1016/j.jsha.2012.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
281 Kirk JK, Craven T, Lipkin EW, Katula J, Pedley C, O'Connor PJ, Margolis KL. Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD trial. Diabetes Res Clin Pract 2013;100:61-8. [PMID: 23490598 DOI: 10.1016/j.diabres.2013.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
282 Siddiqui MS, Sanyal AJ. Drug Therapy for NASH: Insulin-Sensitizing Agents (Metformin and Thiazolidinediones). Non-Alcoholic Fatty Liver Disease 2013. [DOI: 10.1002/9781118556153.ch24] [Reference Citation Analysis]
283 Neff KJ, Roux CWL. Incretins: new targets for the prevention of diabetes and obesity. Clinical Lipidology 2013;8:109-121. [DOI: 10.2217/clp.12.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
284 Davis-Lameloise N, Hernan A, Janus ED, Stewart E, Carter R, Bennett CM, O'Reilly S, Philpot B, Vartiainen E, Dunbar JA; Melbourne Diabetes Prevention Study (MDPS) research group. The Melbourne Diabetes Prevention Study (MDPS): study protocol for a randomized controlled trial. Trials 2013;14:31. [PMID: 23369724 DOI: 10.1186/1745-6215-14-31] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
285 Rowe MW, Bergman RN, Wagenknecht LE, Kolberg JA. Performance of a multi-marker diabetes risk score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort. Diabetes Metab Res Rev 2012;28:519-26. [PMID: 22492485 DOI: 10.1002/dmrr.2305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
286 Cohen P, Plutzky J. Diabetes and the Cardiovascular System. Essential Cardiology 2013. [DOI: 10.1007/978-1-4614-6705-2_41] [Reference Citation Analysis]
287 Kabadi UM. Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes. JDM 2013;03:129-133. [DOI: 10.4236/jdm.2013.33019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
288 Suvag S, Utzschneider KM, Kahn SE. Treatment with Thiazolidinediones. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_9] [Reference Citation Analysis]
289 Opie LH, Meier J. Metabolic syndrome, hyperglycemia, and type 2 diabetes. Drugs for the Heart 2013. [DOI: 10.1016/b978-1-4557-3322-4.00020-x] [Reference Citation Analysis]
290 Lim S, Honek J, Cao Y. Blood Vessels in White and Brown Adipose Tissues. Angiogenesis in Adipose Tissue 2013. [DOI: 10.1007/978-1-4614-8069-3_5] [Reference Citation Analysis]
291 Ahrén B. Glucose: Glucose Tolerance. Encyclopedia of Human Nutrition 2013. [DOI: 10.1016/b978-0-12-375083-9.00134-3] [Reference Citation Analysis]
292 Matfin G, Pratley RE. Advances in the treatment of prediabetes. Ther Adv Endocrinol Metab 2010;1:5-14. [PMID: 23148144 DOI: 10.1177/2042018810366429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
293 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
294 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
295 Bose KS, Gupta SK, Vyas P. Adipocytokine levels in genetically high risk for type 2 diabetes in the Indian population: a cross-sectional study. Exp Diabetes Res 2012;2012:386524. [PMID: 23213322 DOI: 10.1155/2012/386524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
296 Ohshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, Min LJ, Ogimoto A, Dahlöf B, Steckelings UM, Unger T, Higaki J, Horiuchi M. Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One 2012;7:e48387. [PMID: 23155382 DOI: 10.1371/journal.pone.0048387] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
297 Carney GA, Bassett K, Wright JM, Dormuth CR. Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study. BMJ Open 2012;2:e001910. [PMID: 23148347 DOI: 10.1136/bmjopen-2012-001910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Freeman JS, Horton ES. What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. American Journal of Therapeutics 2012;19:449-64. [DOI: 10.1097/mjt.0b013e31826fc5e5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
299 Borghi C, Cicero AF. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. High Blood Press Cardiovasc Prev 2012;19:19-31. [PMID: 22670584 DOI: 10.2165/11632100-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
300 Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16:33-43. [PMID: 22276251 DOI: 10.4103/2230-8210.91183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
301 Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 2013;161:145-55. [PMID: 23022285 DOI: 10.1016/j.trsl.2012.08.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
302 Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012;15:217-28. [PMID: 22612607 DOI: 10.3109/13697137.2012.656401] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
303 Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs 2009;9:163-76. [PMID: 19463022 DOI: 10.1007/BF03256573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
304 Hsu WC, Boyko EJ, Fujimoto WY, Kanaya A, Karmally W, Karter A, King GL, Look M, Maskarinec G, Misra R. Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications. Diabetes Care. 2012;35:1189-1198. [PMID: 22517940 DOI: 10.2337/dc12-0212] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
305 Ohshima K, Mogi M, Horiuchi M. Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Int J Vasc Med 2012;2012:508416. [PMID: 22888436 DOI: 10.1155/2012/508416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
306 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2012. [DOI: 10.1002/14651858.cd009989] [Reference Citation Analysis]
307 Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8:639-649. [PMID: 22751341 DOI: 10.1038/nrendo.2012.96] [Cited by in Crossref: 344] [Cited by in F6Publishing: 359] [Article Influence: 34.4] [Reference Citation Analysis]
308 Piguel X, Hadjadj S. Stratégie thérapeutique dans le traitement du diabète de type 2. EMC - Endocrinologie - Nutrition 2012;9:1-8. [DOI: 10.1016/s1155-1941(12)53865-5] [Reference Citation Analysis]
309 Amato AA, de Assis Rocha Neves F. Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res 2012;2012:978687. [PMID: 22745632 DOI: 10.1155/2012/978687] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
310 Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-51. [PMID: 22683134 DOI: 10.1016/S0140-6736(12)60525-X] [Cited by in Crossref: 288] [Cited by in F6Publishing: 313] [Article Influence: 28.8] [Reference Citation Analysis]
311 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
312 Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64. [PMID: 22681705 DOI: 10.1186/1475-2840-11-64] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
313 Huang JV, Greyson CR, Schwartz GG. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res 2012;53:1738-54. [PMID: 22685322 DOI: 10.1194/jlr.R024505] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
314 Zhang YH, Ma WJ, Thomas GN, Xu YJ, Lao XQ, Xu XJ, Song XL, Xu HF, Cai QM, Xia L, Nie SP, Deng HH, Yu IT. Diabetes and pre-diabetes as determined by glycated haemoglobin A1c and glucose levels in a developing southern Chinese population. PLoS One 2012;7:e37260. [PMID: 22615957 DOI: 10.1371/journal.pone.0037260] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
315 Heald AH, Knapman H, Nair S, Chambers T, Radford D, Rushton T, Anderson SG. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile. Prim Care Diabetes 2012;6:213-9. [PMID: 22560663 DOI: 10.1016/j.pcd.2012.02.002] [Reference Citation Analysis]
316 Tolkacheva VV, Villevalde SV, Kobalava ZD. Carbohydrate metabolism and transformation of pre-diabetes into type 2 diabetes mellitus depending on diagnostic methods in nondiabetic patients with hypertension and high cardiovascular risk. Arter gipertenz 2012;18:83-95. [DOI: 10.18705/1607-419x-2012-18-2-83-95] [Reference Citation Analysis]
317 Frazier-Wood AC, Garvey WT, Dall T, Honigberg R, Pourfarzib R. Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Relat Disord 2012;10:244-51. [PMID: 22533466 DOI: 10.1089/met.2011.0148] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
318 Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res 2012;110:8-11. [PMID: 22223206 DOI: 10.1161/RES.0b013e3182435d88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
319 Sinclair AJ, Meneilly GS. Diabetes Mellitus. Pathy's Principles and Practice of Geriatric Medicine 2012. [DOI: 10.1002/9781119952930.ch101] [Reference Citation Analysis]
320 Home P, Almaatouq M. Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5–8 December 2011. Diabetes & Vascular Disease 2012;12:101-108. [DOI: 10.1177/1474651412443389] [Reference Citation Analysis]
321 Laguardia HA, Hamm LL, Chen J. The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies. J Nutr Metab 2012;2012:652608. [PMID: 22523674 DOI: 10.1155/2012/652608] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
322 Marini MA, Succurro E, Frontoni S, Mastroianni S, Arturi F, Sciacqua A, Lauro R, Hribal ML, Perticone F, Sesti G. Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 2012;35:868-72. [PMID: 22357182 DOI: 10.2337/dc11-2181] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
323 Buchanan TA, Page KA. Approach to the patient with gestational diabetes after delivery. J Clin Endocrinol Metab 2011;96:3592-8. [PMID: 22143829 DOI: 10.1210/jc.2011-1515] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
324 Davidson MB. Counterpoint: postprandial glucose levels are not a clinically important treatment target. Diabetes Care 2010;33:1908-10. [PMID: 20668159 DOI: 10.2337/dc10-0712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
325 Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL. Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One 2012;7:e30063. [PMID: 22253880 DOI: 10.1371/journal.pone.0030063] [Cited by in Crossref: 143] [Cited by in F6Publishing: 151] [Article Influence: 14.3] [Reference Citation Analysis]
326 Feng Y, Yang Y, Ma X, Chen K, Wu N, Wang D, Li P, Wang M, Li Q, Zhang J. Prevalence of diabetes among Han, Manchu and Korean ethnicities in the Mudanjiang area of China: a cross-sectional survey. BMC Public Health 2012;12:23. [PMID: 22233562 DOI: 10.1186/1471-2458-12-23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
327 Karam JG, Mcfarlane SI. Prevention of Type 2 Diabetes: Evidence from Clinical Trials. Diabetes and Hypertension 2012. [DOI: 10.1007/978-1-60327-357-2_12] [Reference Citation Analysis]
328 Carrillo-iregui A, Gomez-meade C. Pharmacological Therapies of Metabolic Syndrome. Pediatric Metabolic Syndrome 2012. [DOI: 10.1007/978-1-4471-2366-8_16] [Reference Citation Analysis]
329 Barzilay J. The Pre-Diabetic, Insulin-Resistant State. The Epidemiology of Aging 2012. [DOI: 10.1007/978-94-007-5061-6_25] [Reference Citation Analysis]
330 Gaziano JM, Ridker PM, Libby P. Primary and Secondary Prevention of Coronary Heart Disease. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2012. [DOI: 10.1016/b978-1-4377-0398-6.00049-4] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
331 McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J. Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis 2011;10:217. [PMID: 22107734 DOI: 10.1186/1476-511X-10-217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
332 Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4:249-263. [PMID: 21765869 DOI: 10.1177/1756283x11403809] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
333 Cernea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud. 2011;8:323-338. [PMID: 22262070 DOI: 10.1900/rds.2011.8.323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
334 Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:325-34. [PMID: 21922031 DOI: 10.1177/1756283X11409793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
335 Garber AJ. Incretin therapy--present and future. Rev Diabet Stud. 2011;8:307-322. [PMID: 22262069 DOI: 10.1900/rds.2011.8.307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
336 Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 2011;162:938-948.e2. [PMID: 22093212 DOI: 10.1016/j.ahj.2011.07.030] [Cited by in Crossref: 115] [Cited by in F6Publishing: 123] [Article Influence: 10.5] [Reference Citation Analysis]
337 Seguí Díaz M, Mediavilla Bravo J, Comas Samper J, Barquilla García A, Carramiñana Barrera F. Prevención de la diabetes mellitus 2. SEMERGEN - Medicina de Familia 2011;37:496-503. [DOI: 10.1016/j.semerg.2011.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Szentandrássy N, Harmati G, Bárándi L, Simkó J, Horváth B, Magyar J, Bányász T, Lorincz I, Szebeni A, Kecskeméti V, Nánási PP. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells. Br J Pharmacol 2011;163:499-509. [PMID: 21232044 DOI: 10.1111/j.1476-5381.2011.01215.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
339 Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011;34:1601-4. [PMID: 21709296 DOI: 10.2337/dc11-0046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
340 Kahn SE, Utzschneider KM. What's next for diabetes prevention? Diabetes Care 2011;34:1678-80. [PMID: 21709302 DOI: 10.2337/dc11-0694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
341 Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011;77:1487-93. [PMID: 21917767 DOI: 10.1212/WNL.0b013e318232ac1a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 7.5] [Reference Citation Analysis]
342 Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011;32:734-9. [PMID: 21880378 DOI: 10.1016/j.tips.2011.07.006] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 9.4] [Reference Citation Analysis]
343 Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169. [PMID: 21791495 DOI: 10.1136/bmj.d4169] [Cited by in Crossref: 514] [Cited by in F6Publishing: 537] [Article Influence: 46.7] [Reference Citation Analysis]
344 Sullivan SD, Ratner RE. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011;11:91-8. [PMID: 21207204 DOI: 10.1007/s11892-010-0170-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
345 Abdul-Ghani MA, Abdul-Ghani T, Stern MP, Karavic J, Tuomi T, Bo I, Defronzo RA, Groop L. Two-step approach for the prediction of future type 2 diabetes risk. Diabetes Care 2011;34:2108-12. [PMID: 21788628 DOI: 10.2337/dc10-2201] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
346 Mehta SR, Kashyap AS, Das S. Diabetes Mellitus in India: The Modern Scourge. Med J Armed Forces India 2009;65:50-4. [PMID: 27408191 DOI: 10.1016/S0377-1237(09)80056-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
347 Yamada E, Lee TW, Pessin JE, Bastie CC. Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance. Future Med Chem 2010;2:1785-96. [PMID: 21428801 DOI: 10.4155/fmc.10.264] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
348 Calkin AC, Thomas MC. PPAR Agonists and Cardiovascular Disease in Diabetes. PPAR Res 2008;2008:245410. [PMID: 18288280 DOI: 10.1155/2008/245410] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
349 Robinson JG. Should We Use PPAR Agonists to Reduce Cardiovascular Risk? PPAR Res 2008;2008:891425. [PMID: 18288293 DOI: 10.1155/2008/891425] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
350 Gurnell M. 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. PPAR Res 2007;2007:83593. [PMID: 17389771 DOI: 10.1155/2007/83593] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
351 Mohamedali HZ, Breunis H, Timilshina N, Alibhai SM. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J 2011;5:28-32. [PMID: 21470509 DOI: 10.5489/cuaj.09172] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
352 Rahman S, Ismail AA, Rahman AR. Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope? Int J Diabetes Dev Ctries 2009;29:110-7. [PMID: 20165647 DOI: 10.4103/0973-3930.54287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
353 Erol A. The Functions of PPARs in Aging and Longevity. PPAR Res 2007;2007:39654. [PMID: 18317516 DOI: 10.1155/2007/39654] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
354 DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34 Suppl 2:S202-9. [PMID: 21525456 DOI: 10.2337/dc11-s221] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
355 Pfützner A, Hanefeld M, Dekordi LA, Müller J, Kleine I, Fuchs W, Forst T. Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. J Diabetes Sci Technol 2011;5:989-98. [PMID: 21880242 DOI: 10.1177/193229681100500422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
356 Ortega Basagoiti R. Peregrinaje de un antidiabético hasta su aprobación por las agencias internacionales del medicamento. Situación actual. Avances en Diabetología 2011;27:107-114. [DOI: 10.1016/j.avdiab.2011.08.001] [Reference Citation Analysis]
357 Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:1036-47. [PMID: 20977574 DOI: 10.1111/j.1463-1326.2010.01299.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
358 Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010;6:657-691. [PMID: 20932114 DOI: 10.2217/fca.10.86] [Cited by in Crossref: 94] [Cited by in F6Publishing: 99] [Article Influence: 8.5] [Reference Citation Analysis]
359 Lu YH, Lu JM, Wang SY, Li CL, Zheng RP, Tian H, Wang XL. Outcome of intensive integrated intervention in participants with impaired glucose regulation in China. Adv Ther 2011;28:511-9. [PMID: 21533568 DOI: 10.1007/s12325-011-0022-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
360 Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33:46-62. [PMID: 21622851 DOI: 10.1093/epirev/mxq019] [Cited by in Crossref: 185] [Cited by in F6Publishing: 199] [Article Influence: 16.8] [Reference Citation Analysis]
361 Palee S, Chattipakorn S, Phrommintikul A, Chattipakorn N. PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World J Cardiol 2011; 3(5): 144-152 [PMID: 21666815 DOI: 10.4330/wjc.v3.i5.144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
362 Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs 2011;71:123-30. [PMID: 21275442 DOI: 10.2165/11585300-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
363 American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011;34 Suppl 1:S11-S61. [PMID: 21193625 DOI: 10.2337/dc11-s011] [Cited by in Crossref: 1811] [Cited by in F6Publishing: 2033] [Article Influence: 164.6] [Reference Citation Analysis]
364 DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care. 2011;34:1265-1269. [PMID: 21515846 DOI: 10.2337/dc10-1567] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
365 Wang M. Current Antidiabetic Therapies and Mechanisms. Metabolic Syndrome 2011. [DOI: 10.1002/9780470910016.ch10] [Reference Citation Analysis]
366 Souto SB, Souto EB, Braga DC, Medina JL. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 2011;67:653-61. [PMID: 21468743 DOI: 10.1007/s00228-011-1038-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
367 Bloomgarden ZT. Diabetes treatment and cardiovascular safety. Diabetes Care 2011;34:e36-42. [PMID: 21447655 DOI: 10.2337/dc11-0201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
368 Carta AR, Pisanu A, Carboni E. Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinsons Dis 2011;2011:689181. [PMID: 21603186 DOI: 10.4061/2011/689181] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
369 Watanabe RM. Inherited destiny? Genetics and gestational diabetes mellitus. Genome Med 2011;3:18. [PMID: 21457499 DOI: 10.1186/gm232] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
370 Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448-453. [PMID: 21423183 DOI: 10.1038/nm.2307] [Cited by in Crossref: 2121] [Cited by in F6Publishing: 2193] [Article Influence: 192.8] [Reference Citation Analysis]
371 Herman WH. The economics of diabetes prevention. Med Clin North Am 2011;95:373-84, viii. [PMID: 21281839 DOI: 10.1016/j.mcna.2010.11.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
372 Raimundo M, Lopes JA. Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. Cardiol Res Pract 2011;2011:747861. [PMID: 21403897 DOI: 10.4061/2011/747861] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
373 Wen YW, Huang WF, Lee YC, Kuo KN, Tsai CR, Tsai YW. Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of thiazolidinediones for diabetes. BMC Health Serv Res 2011;11:21. [PMID: 21281475 DOI: 10.1186/1472-6963-11-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
374 Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011;10:13. [PMID: 21276223 DOI: 10.1186/1475-2840-10-13] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
375 Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, Sheng Z. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol 2011;10:10. [PMID: 21269478 DOI: 10.1186/1475-2840-10-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
376 Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health 2011;101:399-404. [PMID: 21233426 DOI: 10.2105/AJPH.2010.199844] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 5.7] [Reference Citation Analysis]
377 Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1-23. [PMID: 21134520 DOI: 10.1016/j.metabol.2010.09.010] [Cited by in Crossref: 185] [Cited by in F6Publishing: 205] [Article Influence: 16.8] [Reference Citation Analysis]
378 Blicklé J. Traitement du diabète en dehors de l'insuline. EMC - Endocrinologie - Nutrition 2011;8:1-20. [DOI: 10.1016/s1155-1941(11)48522-x] [Reference Citation Analysis]
379 Consoli A. New therapeutic algorithm of Type 2 diabetes: lights and shadows. J Endocrinol Invest 2011;34:65-8. [PMID: 21297380 DOI: 10.1007/BF03346697] [Reference Citation Analysis]
380 Carrero JJ, Stenvinkel P, Lindholm B. Endocrine Aspects of Chronic Kidney Disease. Brenner and Rector's The Kidney 2011. [DOI: 10.1016/b978-1-4160-6193-9.10057-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
381 Codario RA. Guidelines and Classifications. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome 2011. [DOI: 10.1007/978-1-60327-441-8_2] [Reference Citation Analysis]
382 Sorrentino MJ. The Metabolic Syndrome. Hyperlipidemia in Primary Care 2011. [DOI: 10.1007/978-1-60327-502-6_2] [Reference Citation Analysis]
383 Reasner C. The Metabolic Syndrome: 2009. Comprehensive Cardiovascular Medicine in the Primary Care Setting 2011. [DOI: 10.1007/978-1-60327-963-5_7] [Reference Citation Analysis]
384 Gore MO, Inzucchi SE, Mcguire DK. Diabetes and Cardiovascular Disease. Preventive Cardiology: Companion to Braunwald's Heart Disease 2011. [DOI: 10.1016/b978-1-4377-1366-4.00021-4] [Reference Citation Analysis]
385 Westerhaus B, Gosmanov AR, Umpierrez GE. Diabetes prevention: can insulin secretagogues do the job? Prim Care Diabetes 2011;5:73-80. [PMID: 21185798 DOI: 10.1016/j.pcd.2010.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
386 Jaber LA, Pinelli NR, Brown MB, Funnell MM, Anderson R, Hammad A, Herman WH. Feasibility of group lifestyle intervention for diabetes prevention in Arab Americans. Diabetes Res Clin Pract 2011;91:307-15. [PMID: 21168232 DOI: 10.1016/j.diabres.2010.11.032] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
387 Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010;52:2206-15. [PMID: 21105109 DOI: 10.1002/hep.24042] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
388 DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011;54:487-95. [DOI: 10.1007/s00125-010-1985-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
389 Imperatore G, Linder B, Pettitt DJ. Diabetes in the Young. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0027] [Reference Citation Analysis]
390 Ramachandran A, Snehalatha C. Diabetes Prevention and Control Programs in Developing Countries. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
391 Knowler WC, Hoskin M, Curtis JM, Nelson RG, Hanson RL. Prevention of Type 2 Diabetes. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0015] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
392 Stolar MW. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clin Proc 2010;85:S50-9. [PMID: 21106864 DOI: 10.4065/mcp.2010.0471] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
393 Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Li H, Jiang Y, Shuai Y. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54:300-307. [PMID: 21046360 DOI: 10.1007/s00125-010-1948-9] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 12.6] [Reference Citation Analysis]
394 Gray LJ, Tringham JR, Davies MJ, Webb DR, Jarvis J, Skinner TC, Farooqi AM, Khunti K. Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study. Vasc Health Risk Manag 2010;6:837-42. [PMID: 20957129 DOI: 10.2147/VHRM.S12504] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
395 Chang EM, Kozak BM, Close KL. Diabetes News. J Diabetes 2010. [PMID: 20923504 DOI: 10.1111/j.1753-0407.2010.00097.x] [Reference Citation Analysis]
396 Ferrante G, Zavalloni D, Corrada E, Presbitero P. Rosiglitazone plus metformin to prevent type 2 diabetes mellitus. The Lancet 2010;376:1387-1388. [DOI: 10.1016/s0140-6736(10)61948-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
397 Chamnan P, Simmons RK, Jackson R, Khaw KT, Wareham NJ, Griffin SJ. Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia 2011;54:291-9. [PMID: 20859613 DOI: 10.1007/s00125-010-1914-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
398 Greenberg BH, Barnard DD. Preventing Heart Failure. Management of Heart Failure 2010. [DOI: 10.1002/9780470669402.ch1] [Reference Citation Analysis]
399 Hunt KJ, Logan SL, Conway DL, Korte JE. Postpartum screening following GDM: how well are we doing? Curr Diab Rep 2010;10:235-41. [PMID: 20425588 DOI: 10.1007/s11892-010-0110-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
400 Carlsson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 2010;20:711-22. [PMID: 20413858 DOI: 10.3233/JAD-2010-100012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 6.1] [Reference Citation Analysis]
401 Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671-90. [PMID: 20859539 DOI: 10.2147/vhrm.s4852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
402 Verner Codoceo R. Prevención de diabetes mellitus 2. Revista Médica Clínica Las Condes 2010;21:741-748. [DOI: 10.1016/s0716-8640(10)70595-2] [Reference Citation Analysis]
403 Fajans SS, Herman WH, Oral EA. Insufficient sensitivity of hemoglobin A(₁C) determination in diagnosis or screening of early diabetic states. Metabolism 2011;60:86-91. [PMID: 20723948 DOI: 10.1016/j.metabol.2010.06.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
404 Distefano JK, Watanabe RM. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel). 2010;3:2610-2646. [PMID: 20936101 DOI: 10.3390/ph3082610] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 5.0] [Reference Citation Analysis]
405 References. Diabetic Neurology 2010. [DOI: 10.3109/9781420085549-19] [Reference Citation Analysis]
406 Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes 2010;3:43-51. [PMID: 22879786 DOI: 10.4137/cmed.s5372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
407 Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33:2190-2195. [PMID: 20628087 DOI: 10.2337/dc10-0752] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 7.3] [Reference Citation Analysis]
408 Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S; DREAM investigators. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care 2010;33:2250-3. [PMID: 20628086 DOI: 10.2337/dc10-0452] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
409 Bailey CJ, Krentz AJ. Oral Antidiabetic Agents. Textbook of Diabetes 2010. [DOI: 10.1002/9781444324808.ch29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
410 Succurro E, Arturi F, Lugarà M, Grembiale A, Fiorentino TV, Caruso V, Andreozzi F, Sciacqua A, Hribal ML, Perticone F. One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin J Am Soc Nephrol. 2010;5:1922-1927. [PMID: 20595688 DOI: 10.2215/cjn.03240410] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 5.4] [Reference Citation Analysis]
411 Gerstein HC, Yusuf S. Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: implications for the evaluation of antidiabetic drugs. Am Heart J 2010;160:1-2. [PMID: 20598964 DOI: 10.1016/j.ahj.2010.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
412 Chan WP, Sverdlov AL, Horowitz JD. Management of the metabolic syndrome in cardiovascular disease. Curr Treat Options Cardiovasc Med 2008;10:27-38. [PMID: 18325305 DOI: 10.1007/s11936-008-0004-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
413 Lü Q, Ke L-, Tong N, Cao L, Wu T, Zhang J; Cochrane Metabolic and Endocrine Disorders Group. Metformin for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd008558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
414 Anselmino M, Malmberg K, Mellbin L, Rydén L. Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Rev Endocr Metab Disord. 2010;11:87-94. [PMID: 20204530 DOI: 10.1007/s11154-010-9136-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
415 Ramachandran A, Arun N, Shetty AS, Snehalatha C. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). Diabetes Care 2010;33:2164-8. [PMID: 20519663 DOI: 10.2337/dc09-1150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
416 Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010;37:1136-42. [PMID: 20436082 DOI: 10.3899/jrheum.090994] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 8.3] [Reference Citation Analysis]
417 Freemark M. Childhood Obesity. Brook's Clinical Pediatric Endocrinology 2010. [DOI: 10.1002/9781444316728.ch20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
418 American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 Suppl 1:S11-S61. [PMID: 20042772 DOI: 10.2337/dc10-s011] [Cited by in Crossref: 2086] [Cited by in F6Publishing: 2353] [Article Influence: 173.8] [Reference Citation Analysis]
419 Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, Hanefeld M, Lehmann R, Malecki MT, Nesto R, Pirags V, Scheen A, Seufert J, Sjohölm A, Tsatsoulis A, DeFronzo R. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69. [PMID: 20352408 DOI: 10.1007/s00125-010-1702-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
420 Psaty BM. Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture. Circulation 2010;121:940-5. [PMID: 20177009 DOI: 10.1161/CIRCULATIONAHA.109.933705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
421 Cao H, Ren M, Guo L, Shang H, Zhang J, Song Y, Wang H, Wang B, Li X, Hu J, Wang X, Wang D, Chen J, Li S, Chen L. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial. Trials 2010;11:27. [PMID: 20214831 DOI: 10.1186/1745-6215-11-27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
422 Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, Thiemermann C, Fantozzi R. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 2010;160:1892-902. [PMID: 20233219 DOI: 10.1111/j.1476-5381.2010.00671.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
423 Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010;55:283-93. [PMID: 20117431 DOI: 10.1016/j.jacc.2009.07.029] [Cited by in Crossref: 144] [Cited by in F6Publishing: 154] [Article Influence: 12.0] [Reference Citation Analysis]
424 Sheehan JP. Bad medicine: there is a lot wrong with diabetes care in the United States. Cult Med Psychiatry 2010;34:2-12. [PMID: 20066481 DOI: 10.1007/s11013-009-9158-y] [Reference Citation Analysis]
425 Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, Barnett J, Henson J, Hiles S, Farooqi A, Griffin SJ, Wareham NJ, Davies MJ. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010;11:16. [PMID: 20170482 DOI: 10.1186/1745-6215-11-16] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
426 Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem. 2010;285:9311-9316. [PMID: 20129921 DOI: 10.1074/jbc.r109.025031] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
427 Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S194-S198. [PMID: 19875551 DOI: 10.2337/dc09-s309] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 6.9] [Reference Citation Analysis]
428 Garber AJ. Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy. Diabetes Care 2009;32 Suppl 2:S184-8. [PMID: 19875549 DOI: 10.2337/dc09-S307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
429 Harrison SA. Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? Hepatology 2010;51:366-9. [PMID: 20101743 DOI: 10.1002/hep.23473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
430 Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824-831. [PMID: 20118174 DOI: 10.1093/eurheartj/ehp604] [Cited by in Crossref: 168] [Cited by in F6Publishing: 174] [Article Influence: 14.0] [Reference Citation Analysis]
431 Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, Ido Y. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 2010;298:E751-60. [PMID: 20103737 DOI: 10.1152/ajpendo.00745.2009] [Cited by in Crossref: 568] [Cited by in F6Publishing: 608] [Article Influence: 47.3] [Reference Citation Analysis]
432 Pscherer S, Heemann U, Frank H. Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010;33:914-9. [PMID: 20086255 DOI: 10.2337/dc09-1381] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
433 Magalhães ME, Cavalcanti BA, Cavalcanti S. Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist. Diabetol Metab Syndr 2010;2:2. [PMID: 20205782 DOI: 10.1186/1758-5996-2-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
434 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2010. [DOI: 10.1007/978-0-387-09841-8_50] [Reference Citation Analysis]
435 Stetson B, Mokshagundam SPL. Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. Preventive Nutrition 2010. [DOI: 10.1007/978-1-60327-542-2_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Ruderman N, Shulman GI. The Metabolic Syndrome. Endocrinology 2010. [DOI: 10.1016/b978-1-4160-5583-9.00044-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Watanabe RM. Genetics of Gestational Diabetes Mellitus and Type 2 Diabetes. Gestational Diabetes During and After Pregnancy 2010. [DOI: 10.1007/978-1-84882-120-0_13] [Reference Citation Analysis]
438 Dungan KM, Buse JB. Management of Type 2 Diabetes Mellitus. Endocrinology 2010. [DOI: 10.1016/b978-1-4160-5583-9.00048-4] [Reference Citation Analysis]
439 Luchsinger JA. The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer’s Disease: An Epidemiological Perspective. Diabetes, Insulin and Alzheimer's Disease 2010. [DOI: 10.1007/978-3-642-04300-0_7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
440 Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010;33:608-13. [PMID: 20009095 DOI: 10.2337/dc09-1579] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
441 DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke DC, Stentz FD, Tripathy D; ACT NOW Study Group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010;53:435-45. [PMID: 20012012 DOI: 10.1007/s00125-009-1614-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
442 Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care 2010;33:396-401. [PMID: 19933993 DOI: 10.2337/dc09-1493] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
443 Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86. [PMID: 19878986 DOI: 10.1016/S0140-6736(09)61457-4] [Cited by in Crossref: 1908] [Cited by in F6Publishing: 2056] [Article Influence: 146.8] [Reference Citation Analysis]
444 Pagel-Langenickel I, Bao J, Pang L, Sack MN. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev 2010;31:25-51. [PMID: 19861693 DOI: 10.1210/er.2009-0003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 110] [Article Influence: 8.2] [Reference Citation Analysis]
445 Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metab 2010;21:223-9. [PMID: 19864158 DOI: 10.1016/j.tem.2009.10.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 144] [Article Influence: 9.8] [Reference Citation Analysis]
446 Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KM, Kolm P, Twombly JG, Phillips LS. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010;33:49-54. [PMID: 19808929 DOI: 10.2337/dc09-0341] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
447 Taylor C, Hobbs FD. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Br J Gen Pract. 2009;59:520-524. [PMID: 19567003 DOI: 10.3399/bjgp09x453440] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
448 Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009;32:1207-1212. [PMID: 19564473 DOI: 10.2337/dc08-1935] [Cited by in Crossref: 122] [Cited by in F6Publishing: 130] [Article Influence: 9.4] [Reference Citation Analysis]
449 Sadikot S. Putting the RECORD straight? Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2009;3:178-87. [DOI: 10.1016/j.dsx.2009.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
450 Aljada A, Shah KA, Mousa SA. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res 2009;2009:460764. [PMID: 19696948 DOI: 10.1155/2009/460764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
451 Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr Diab Rep 2009;9:215-20. [PMID: 19490823 DOI: 10.1007/s11892-009-0035-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
452 McFarlane SI. Antidiabetic medications and weight gain: implications for the practicing physician. Curr Diab Rep 2009;9:249-54. [PMID: 19490828 DOI: 10.1007/s11892-009-0040-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
453 Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009;9:193-9. [PMID: 19490820 DOI: 10.1007/s11892-009-0032-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 6.4] [Reference Citation Analysis]
454 Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009;18:437-47. [PMID: 19235778 DOI: 10.1002/pds.1722] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
455 Cefalu WT. Primary Prevention of Type 2 Diabetes: There Are No Simple Solutions! Diabetes 2009;58:1730-1731. [DOI: 10.2337/db09-0840] [Reference Citation Analysis]
456 Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 2009;9:17. [PMID: 19640291 DOI: 10.1186/1472-6823-9-17] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
457 Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, Pennell DJ. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009;11:24. [PMID: 19635160 DOI: 10.1186/1532-429X-11-24] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
458 Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol. 2009;158:429-441. [PMID: 19627285 DOI: 10.1111/j.1476-5381.2009.00349.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
459 Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SB, Nanditha A, Ramachandran A. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care. 2009;32:1796-1801. [PMID: 19587369 DOI: 10.2337/dc09-0676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
460 Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF;  Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009;32:1583-1588. [PMID: 19587364 DOI: 10.2337/dc09-0523] [Cited by in Crossref: 121] [Cited by in F6Publishing: 128] [Article Influence: 9.3] [Reference Citation Analysis]
461 Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis. 2009;16:693-704. [PMID: 19387106 DOI: 10.3233/jad-2009-1022] [Cited by in Crossref: 138] [Cited by in F6Publishing: 160] [Article Influence: 10.6] [Reference Citation Analysis]
462 Florez JC. Genetic susceptibility to type 2 diabetes and implications for therapy. J Diabetes Sci Technol 2009;3:690-6. [PMID: 20144315 DOI: 10.1177/193229680900300413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
463 Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 2009;5:361-8. [PMID: 19475773 DOI: 10.2147/vhrm.s4331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
464 Viljoen A, Sinclair A. Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vasc Health Risk Manag 2009;5:389-95. [PMID: 19475776 DOI: 10.2147/vhrm.s4053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
465 Lennon R, Welsh GI, Singh A, Satchell SC, Coward RJ, Tavaré JM, Mathieson PW, Saleem MA. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009;52:1944-52. [PMID: 19533082 DOI: 10.1007/s00125-009-1423-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
466 Dedov II, Shestakova MV, Vikulova OK. Comments on the Consensus statement of the American Diabetes Association and the European Association for the Studyof Diabetes on the medical management of hyperglycemia in type 2 diabetes. Diabetes mellitus 2009;12:77-82. [DOI: 10.14341/2072-0351-5404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
467 Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215-21. [PMID: 19515410 DOI: 10.1016/S0140-6736(09)60619-X] [Cited by in Crossref: 552] [Cited by in F6Publishing: 576] [Article Influence: 42.5] [Reference Citation Analysis]
468 Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 2009;119:457-65. [PMID: 19183127 DOI: 10.1111/j.1600-0447.2008.01325.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
469 Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009;46:145-54. [PMID: 19194648 DOI: 10.1007/s00592-008-0090-3] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 7.2] [Reference Citation Analysis]
470 Hill AN, Roche C, Appel SJ. Signs of improvement: Diabetes update 2009. The Nurse Practitioner 2009;34:12-22. [DOI: 10.1097/01.npr.0000352283.97228.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
471 Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol 2009;5:365-72. [PMID: 19468288 DOI: 10.1038/nrrheum.2009.102] [Cited by in Crossref: 106] [Cited by in F6Publishing: 108] [Article Influence: 8.2] [Reference Citation Analysis]
472 Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J; Finnish Diabetes Prevention Study Group. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial. PLoS One 2009;4:e5656. [PMID: 19479072 DOI: 10.1371/journal.pone.0005656] [Cited by in Crossref: 124] [Cited by in F6Publishing: 135] [Article Influence: 9.5] [Reference Citation Analysis]
473 American Diabetes Association. Standards of medical care in diabetes--2009. Diabetes Care 2009;32 Suppl 1:S13-61. [PMID: 19118286 DOI: 10.2337/dc09-S013] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1311] [Article Influence: 89.2] [Reference Citation Analysis]
474 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95. [PMID: 19336687 DOI: 10.2337/db09-9028] [Cited by in Crossref: 1737] [Cited by in F6Publishing: 1866] [Article Influence: 133.6] [Reference Citation Analysis]
475 Jiménez Villa J, Argimon Pallàs JM. Análisis e interpretación de un ensayo clínico. FMC - Formación Médica Continuada en Atención Primaria 2009;16:261-271. [DOI: 10.1016/s1134-2072(09)71271-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
476 van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 2008;4:1189-95. [PMID: 19337532 DOI: 10.2147/vhrm.s3119] [Cited by in Crossref: 189] [Cited by in F6Publishing: 196] [Article Influence: 14.5] [Reference Citation Analysis]
477 Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag. 2009;5:141-151. [PMID: 19436665 DOI: 10.2147/vhrm.s4664] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
478 Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009;20:1094-101. [PMID: 19357257 DOI: 10.1681/ASN.2008060579] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
479 Zarich SW, Nesto RW. What have we lost in the wake of the Rosiglitazone Controversy? Endocrine Practice 2009;15:273-274. [DOI: 10.4158/ep.15.3.273] [Reference Citation Analysis]
480 Raef H, Al-mahfouz A, Al-khonaizan A. Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters. International Journal of Diabetes Mellitus 2009;1:2-6. [DOI: 10.1016/j.ijdm.2009.03.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
481 Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab 2009;94:2031-6. [PMID: 19276238 DOI: 10.1210/jc.2008-1348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
482 Ambery P, Pandya B. The new rosiglitazone story: its place today in type 2 diabetes management. Prim Care Diabetes 2009;3:57-9. [PMID: 19269912 DOI: 10.1016/j.pcd.2009.01.002] [Reference Citation Analysis]
483 Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, Shetty AS. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia. 2009;52:1019-1026. [PMID: 19277602 DOI: 10.1007/s00125-009-1315-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
484 Böhler S, Standl E, Senges J, Gitt AK. Myokardinfarktregister unter besonderer Berücksichtigung des Diabetes. Prävention und Versorgungsforschung. [DOI: 10.1007/978-3-540-73042-2_28] [Reference Citation Analysis]
485 Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 2009;418:261-75. [PMID: 19196246 DOI: 10.1042/BJ20082055] [Cited by in Crossref: 304] [Cited by in F6Publishing: 317] [Article Influence: 23.4] [Reference Citation Analysis]
486 Lee JY, Ferlyn TML, Chan A. Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review. The Journal for Nurse Practitioners 2009;5:176-184. [DOI: 10.1016/j.nurpra.2008.09.004] [Reference Citation Analysis]
487 Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG. Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Mol Cell Biol 2009;29:2053-67. [PMID: 19237535 DOI: 10.1128/MCB.01179-08] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 9.0] [Reference Citation Analysis]
488 Koopman RJ, Mainous AG 3rd, Everett CJ, Carter RE. Tool to assess likelihood of fasting glucose impairment (TAG-IT). Ann Fam Med 2008;6:555-61. [PMID: 19001309 DOI: 10.1370/afm.913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
489 van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, Princen HM. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br J Pharmacol 2009;156:1067-75. [PMID: 19220285 DOI: 10.1111/j.1476-5381.2008.00109.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
490 Romero JR, Morris J, Pikula A. Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2008;2:287-303. [PMID: 19124428 DOI: 10.1177/1753944708093847] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 5.2] [Reference Citation Analysis]
491 Basile JN. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract 2009;63:656-66. [PMID: 19220522 DOI: 10.1111/j.1742-1241.2009.02009.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
492 Friedrich JO, Beyene J, Adhikari NK. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. BMC Res Notes 2009;2:5. [PMID: 19134216 DOI: 10.1186/1756-0500-2-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
493 Zinn A, Felson S, Fisher E, Schwartzbard A. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 2008;31:397-403. [PMID: 18781598 DOI: 10.1002/clc.20312] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
494 Wang CCL. Insulin Resistance and Cardiovascular Disease. Insulin Resistance. [DOI: 10.1007/978-1-59745-192-5_12] [Reference Citation Analysis]
495 Ajjan R, Kearney MT, Grant PJ. Insulin Resistance and the Pathogenesis of Cardiovascular Disease. Insulin Resistance. [DOI: 10.1007/978-1-59745-192-5_11] [Reference Citation Analysis]
496 Mackie BD, Harrison DG, Zafari AM. The Metabolic Syndrome. Advances in Vascular Medicine 2009. [DOI: 10.1007/978-1-84882-637-3_23] [Reference Citation Analysis]
497 Stetson B, Mokshagundam SP. Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. Handbook of Clinical Nutrition and Aging 2009. [DOI: 10.1007/978-1-60327-385-5_16] [Reference Citation Analysis]
498 Bottomley JM, Raymond FD. Pharmaco-economic issues for diabetes therapy. Insulin 2009;4:32-60. [DOI: 10.1016/s1557-0843(09)80005-5] [Reference Citation Analysis]
499 Sadikot SM. The Epidemiology of Diabetes in Women and the Looming Epidemic of GDM in the Third World. Diabetes in Women 2009. [DOI: 10.1007/978-1-60327-250-6_12] [Reference Citation Analysis]
500 Florez HJ, Sanchez AA, Marks JB. Type 2 Diabetes. Diabetes and the Brain 2009. [DOI: 10.1007/978-1-60327-850-8_2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
501 Parashar A. N-3 polyunsaturated fatty acids and statins in heart failure. The Lancet 2009;373:379. [DOI: 10.1016/s0140-6736(09)60128-8] [Reference Citation Analysis]
502 Tatti P. The Rise and Fall of Rosiglitazone. Clinical Medicine Therapeutics 2009;1:CMT.S2368. [DOI: 10.4137/cmt.s2368] [Reference Citation Analysis]
503 Opie LH, Miles JM, Smith SC. Metabolic Syndrome, Hyperglycemia, and Type 2 Diabetes. Drugs for the Heart 2009. [DOI: 10.1016/b978-1-4160-6158-8.50016-2] [Reference Citation Analysis]
504 Britov AN. Lechenie sakharnogo diabeta 2-go tipa tiaglitazonami; vliyanie na sostoyanie serdechno-sosudistoy sistemy. Obes metabol 2008;5:11-17. [DOI: 10.14341/2071-8713-5221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
505 Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070-2080. [PMID: 18955635 DOI: 10.1001/archinte.168.19.2070] [Cited by in Crossref: 218] [Cited by in F6Publishing: 235] [Article Influence: 15.6] [Reference Citation Analysis]
506 Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 2009;150:1330-40. [PMID: 18948404 DOI: 10.1210/en.2008-0936] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
507 Gupta M, Braga MB, Verma S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Can J Cardiol 2008;24:e65-9. [PMID: 18841263 DOI: 10.1016/s0828-282x(08)70685-8] [Reference Citation Analysis]
508 Mateos Polo L, Hernndez Criado J, Cubino Bveda N, Garca Mingo A. Antidiab?ticos orales. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:1188-1194. [DOI: 10.1016/s0211-3449(08)73226-0] [Reference Citation Analysis]
509 Gmez Marcos M, Garca Ortiz L. Manejo general y extrahospitalario del paciente con diabetes. Valoraci?n de la sintomatolog?a. Procesos intercurrentes. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:1138-1148. [DOI: 10.1016/s0211-3449(08)73217-x] [Reference Citation Analysis]
510 Robertson C. Translating ADA/EASD Guidelines and the ACE/AACE Road Maps into Primary Care of Patients with Type 2 Diabetes. The Journal for Nurse Practitioners 2008;4:661-71. [DOI: 10.1016/j.nurpra.2008.01.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
511 &NA;. Assessment of cardiovascular risk and simultaneous treatment of multiple risk factors is important in patients with metabolic syndrome. Drugs & Therapy Perspectives 2008;24:13-17. [DOI: 10.2165/00042310-200824090-00004] [Reference Citation Analysis]
512 Gupta D, Jetton TL, Mortensen RM, Duan SZ, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse pdx-1 promoter. J Biol Chem. 2008;283:32462-32470. [PMID: 18718916 DOI: 10.1074/jbc.m801813200] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
513 Bloomgarden ZT. Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. Diabetes Care 2008;31:1461-6. [PMID: 18594064 DOI: 10.2337/dc08-zb07] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
514 Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2008;179:229-234. [PMID: 18663202 DOI: 10.1503/cmaj.080012] [Cited by in Crossref: 284] [Cited by in F6Publishing: 303] [Article Influence: 20.3] [Reference Citation Analysis]
515 Bloomgarden ZT. Approaches to treatment of type 2 diabetes. Diabetes Care 2008;31:1697-703. [PMID: 18663234 DOI: 10.2337/dc08-zb08] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
516 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2007. [DOI: 10.1007/978-3-540-72548-0_12] [Reference Citation Analysis]
517 Mazza AD. Insulin resistance syndrome and glucose dysregulation in the elderly. Clin Geriatr Med 2008;24:437-54, vi. [PMID: 18672181 DOI: 10.1016/j.cger.2008.03.006] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
518 Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 2008;21:852-9. [PMID: 18535538 DOI: 10.1038/ajh.2008.202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
519 Huang JF, Yu ML, Dai CY, Hsieh MY, Hwang SJ, Hsiao PJ, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Shin SJ, Chang WY, Chuang WL. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2008;103:1933-40. [PMID: 18637090 DOI: 10.1111/j.1572-0241.2008.01996.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
520 Norris AW, Hirshman MF, Yao J, Jessen N, Musi N, Chen L, Sivitz WI, Goodyear LJ, Kahn CR. Endogenous peroxisome proliferator-activated receptor-gamma augments fatty acid uptake in oxidative muscle. Endocrinology 2008;149:5374-83. [PMID: 18653710 DOI: 10.1210/en.2008-0100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
521 Doyle A, Desilva P, Koduah D, Birdi J, Sabah M, King R. An insight into undiagnosed impaired glucose regulation. Prim Care Diabetes 2007;1:155-8. [PMID: 18632037 DOI: 10.1016/j.pcd.2007.07.001] [Reference Citation Analysis]
522 Mancini MC, Halpern A. Orlistat in the prevention of diabetes in the obese patient. Vasc Health Risk Manag 2008;4:325-36. [PMID: 18561508 DOI: 10.2147/vhrm.s6808] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
523 Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J 2008;156:23-30. [PMID: 18585493 DOI: 10.1016/j.ahj.2008.03.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
524 Hsueh WA, Handelsman Y. Pharmacologic treatment options for prediabetes. Nat Rev Endocrinol 2008;4:380-381. [DOI: 10.1038/ncpendmet0842] [Reference Citation Analysis]
525 Devers M, Fisher M. Glycaemic control and metabolic risk: getting the extra mile from diabetes control. Pract Diab Int 2008;25:233-6. [DOI: 10.1002/pdi.1260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
526 Grundy S. Prevention and Management of Dyslipidemia and the Metabolic Syndrome in Obese Patients. Handbook of Obesity 2008. [DOI: 10.3109/9781420051452-31] [Reference Citation Analysis]
527 Perreault L, Bergman BC, Playdon MC, Dalla Man C, Cobelli C, Eckel RH. Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab 2008;295:E428-35. [PMID: 18523123 DOI: 10.1152/ajpendo.90354.2008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
528 Ballesteros-pomar MD, León-sanz M. Nutrition in the metabolic syndrome: Pharmacological treatment. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2008;3:e108-e116. [DOI: 10.1016/j.eclnm.2008.02.001] [Reference Citation Analysis]
529 Rotella CM, Pala L. Time to insulin in type-2 diabetes: high hurdles or Santiago way? Acta Diabetol 2008;45:67-74. [PMID: 18408882 DOI: 10.1007/s00592-008-0027-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
530 McDonald SD, Yusuf S, Sheridan P, Anand SS, Gerstein HC; Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Trial Investigators. Dysglycemia and a history of reproductive risk factors. Diabetes Care 2008;31:1635-8. [PMID: 18458144 DOI: 10.2337/dc08-0621] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
531 Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008;3 Suppl 2:S38-48. [PMID: 18309002 DOI: 10.2215/CJN.02650707] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
532 Godbout A, Chiasson JL. Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep 2007;7:333-9. [PMID: 18173965 DOI: 10.1007/s11892-007-0055-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
533 Schwarz PE, Li J, Lindström J, Bergmann A, Gruhl U, Saaristo T, Tuomilehto J. How should the clinician most effectively prevent type 2 diabetes in the obese person at high risk? Curr Diab Rep 2007;7:353-62. [PMID: 18173968 DOI: 10.1007/s11892-007-0058-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
534 Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 2008;118:403-8. [PMID: 18246189 DOI: 10.1172/JCI33296] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 7.6] [Reference Citation Analysis]
535 Redon J, Cífková R. The metabolic syndrome in hypertension: diagnostic and therapeutic implications. Curr Hypertens Rep 2007;9:305-13. [PMID: 17686382 DOI: 10.1007/s11906-007-0056-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
536 Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 2007;9:332-7. [PMID: 17686386 DOI: 10.1007/s11906-007-0060-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
537 Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008;31:1416-21. [PMID: 18356403 DOI: 10.2337/dc07-2390] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 6.3] [Reference Citation Analysis]
538 Ziemer DC, Kolm P, Foster JK, Weintraub WS, Vaccarino V, Rhee MK, Varughese RM, Tsui CW, Koch DD, Twombly JG, Narayan KM, Phillips LS. Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. J Gen Intern Med 2008;23:528-35. [PMID: 18335280 DOI: 10.1007/s11606-008-0524-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
539 Stroup JS. Management of thiazolidinedione-induced oedema: minimizing collateral damage. Diabetes Obes Metab 2008;10:264-265. [DOI: 10.1111/j.1463-1326.2007.00821.x] [Reference Citation Analysis]
540 Martens FM, Visseren FL. The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity. Curr Diab Rep 2007;7:74-81. [PMID: 17254521 DOI: 10.1007/s11892-007-0013-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
541 Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, Phipps RP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost 2008;99:86-95. [PMID: 18217139 DOI: 10.1160/TH07-05-0328] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
542 Cooper-DeHoff RM, Pepine CJ. Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol 2007;30:593-7. [PMID: 17607758 DOI: 10.1002/clc.7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
543 Baxter M. Treatment of type 2 diabetes: a structured management plan. Adv Ther 2008;25:106-14. [PMID: 18330521 DOI: 10.1007/s12325-008-0017-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
544 Dinneen SF. Diabetes? Medicine 2008;36:58-61. [DOI: 10.1016/j.mpmed.2007.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
545 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2008 2008. [DOI: 10.1007/978-3-540-69219-5_11] [Reference Citation Analysis]
546 Park TS, Baek H, Park J. General Principles for Diabetes Mellitus Management. J Korean Med Assoc 2008;51:806. [DOI: 10.5124/jkma.2008.51.9.806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
547 Stulc T, Ceska R. Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm? Medical Hypotheses 2008;70:199-200. [DOI: 10.1016/j.mehy.2007.07.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
548 Lumley T, Rice KM, Psaty BM. Carryover effects after cessation of drug treatment: trophies or dreams? Am J Hypertens 2008;21:14-6. [PMID: 18091738 DOI: 10.1038/ajh.2007.21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
549 Emott M, Freemark M. Treatment of Insulin Resistance in Youth: The Role of Metformin. Energy Metabolism and Obesity. [DOI: 10.1007/978-1-60327-139-4_13] [Reference Citation Analysis]
550 Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia 2008;51:249-57. [PMID: 18060659 DOI: 10.1007/s00125-007-0893-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
551 Nichols GA, Koro CE, Kolatkar NS. The epidemiology of congestive heart failure in hyperglycemia below the threshold for diabetes: A critical review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2007;1:273-8. [DOI: 10.1016/j.dsx.2007.09.004] [Reference Citation Analysis]
552 Current World Literature. Current Opinion in Obstetrics & Gynecology 2007;19:596-605. [DOI: 10.1097/gco.0b013e3282f37e31] [Reference Citation Analysis]
553 Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791-2801. [PMID: 17823655 DOI: 10.1172/jci30335] [Cited by in Crossref: 257] [Cited by in F6Publishing: 263] [Article Influence: 17.1] [Reference Citation Analysis]
554 Parhofer KG, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 2007;6:36. [PMID: 18042288 DOI: 10.1186/1475-2840-6-36] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
555 Mudaliar S, Henry R. Thiazolidinediones. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-12] [Reference Citation Analysis]
556 Mogensen C. Renal Dysfunction and Hypertension. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-20] [Reference Citation Analysis]
557 Del Prato S. A call to action - the UN Resolution on diabetes: A call to action. International Journal of Clinical Practice 2007;61:1-4. [DOI: 10.1111/j.1742-1241.2007.01607.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
558 Matthaei S, Thienel F, Morcos M, Nawroth P. Diabetes mellitus Typ 1 und Typ 2. Medizinische Therapie 2007 | 2008. [DOI: 10.1007/978-3-540-48554-4_35] [Reference Citation Analysis]
559 Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289-294. [PMID: 17959861 DOI: 10.2337/dc07-1338] [Cited by in Crossref: 252] [Cited by in F6Publishing: 268] [Article Influence: 16.8] [Reference Citation Analysis]
560 Martínez M, Real de Asúa D, Torres R, Bernardino J, Pallardo L, García-puig J. Reproducibilidad de la prueba de sobrecarga oral de glucosa en pacientes con glucosa alterada en ayunas. Revista Clínica Española 2007;207:445-7. [DOI: 10.1016/s0014-2565(07)73438-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
561 Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153:636-645. [PMID: 17906687 DOI: 10.1038/sj.bjp.0707452] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 6.5] [Reference Citation Analysis]
562 Laatikainen T, Dunbar JA, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot B, Absetz P, Bunker S, O'Neil A, Reddy P, Best JD, Janus ED. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health 2007;7:249. [PMID: 17877832 DOI: 10.1186/1471-2458-7-249] [Cited by in Crossref: 168] [Cited by in F6Publishing: 178] [Article Influence: 11.2] [Reference Citation Analysis]
563 Greenstone CL. Clinician's Corner: Type 2 Diabetes: A Disease of Epidemic Proportion That Is Largely Preventable—But How? American Journal of Lifestyle Medicine 2007;1:335-338. [DOI: 10.1177/1559827607304785] [Reference Citation Analysis]
564 Karalliedde J, Buckingham RE. Choice of monotherapy in newly diagnosed Type 2 diabetic patients: clinical perspective of ADOPT. Therapy 2007;4:535-540. [DOI: 10.2217/14750708.4.5.535] [Reference Citation Analysis]
565 Miner M. Patient Education: Preventing Progression of Type 2 Diabetes: The Reflex to Use Pharmacological Therapy. American Journal of Lifestyle Medicine 2007;1:358-359. [DOI: 10.1177/1559827607304489.] [Reference Citation Analysis]
566 Erdmann E. Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk. Diabetes & Vascular Disease 2007;7:211-216. [DOI: 10.1177/14746514070070050301] [Reference Citation Analysis]
567 Mohan V, Sandeep S. ‘ADOPT’ and ‘DREAM’ trials and the Indian perspective. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2007;1:189-92. [DOI: 10.1016/j.dsx.2007.06.003] [Reference Citation Analysis]
568 Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497. [PMID: 17761999 DOI: 10.1136/bmj.39314.620174.80] [Cited by in Crossref: 245] [Cited by in F6Publishing: 255] [Article Influence: 16.3] [Reference Citation Analysis]
569 Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007;6:20. [PMID: 17697384 DOI: 10.1186/1475-2840-6-20] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
570 Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep. 2007;7:228-234. [PMID: 17547840 DOI: 10.1007/s11892-007-0036-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
571 Pfützner A, Forst T. A Diabetes Outcome and Progression Trial – Die ADOPT Studie. Diabetologe 2007;3:261-269. [DOI: 10.1007/s11428-007-0138-y] [Reference Citation Analysis]
572 Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9. [PMID: 17559148 DOI: 10.1002/hep.21661] [Cited by in Crossref: 182] [Cited by in F6Publishing: 194] [Article Influence: 12.1] [Reference Citation Analysis]
573 Standl E. DREAM-Studie. Diabetologe 2007;3:278-281. [DOI: 10.1007/s11428-007-0143-1] [Reference Citation Analysis]
574 Grant PJ. Rosiglitazone and cardiovascular disease: a diabetologist's perspective. Diab Vasc Dis Res 2007;4:75-6. [PMID: 17654437 DOI: 10.3132/dvdr.2007.021] [Reference Citation Analysis]
575 Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J 2007;154:137-43. [PMID: 17584566 DOI: 10.1016/j.ahj.2007.03.029] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
576 Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007;67:997-1026. [PMID: 17488145 DOI: 10.2165/00003495-200767070-00005] [Cited by in Crossref: 94] [Cited by in F6Publishing: 103] [Article Influence: 6.3] [Reference Citation Analysis]
577 Howat I, Cleland SJ. Should we now ADOPT glitazones earlier in treatment of type 2 diabetes? International Journal of Clinical Practice 2007;61:1071-1073. [DOI: 10.1111/j.1742-1241.2007.01408.x] [Reference Citation Analysis]
578 Marre M, Travert F, Duval-leclercq M. Comment je prends en charge les œdèmes associés à la prise de glitazones. Médecine des Maladies Métaboliques 2007;1:57-58. [DOI: 10.1016/s1957-2557(07)88631-7] [Reference Citation Analysis]
579 Moulin P. Les traitements à visée métabolique: «de la biochimie à la paroi». La Revue de Médecine Interne 2007;28:S12-S13. [DOI: 10.1016/j.revmed.2007.03.012] [Reference Citation Analysis]
580 Gæde P, Pedersen O. Rosiglitazone monotherapy for type 2 diabetes mellitus—too soon to ADOPT? Nat Rev Endocrinol 2007;3:456-457. [DOI: 10.1038/ncpendmet0503] [Reference Citation Analysis]
581 Roussel R. Trois études dans le diabéte de type 2: DREAM Résultats de suivi post-intervention (wash-out). Annales d'Endocrinologie 2007;68:36-38. [DOI: 10.1016/s0003-4266(07)80009-6] [Reference Citation Analysis]
582 Montori VM, Isley WL, Guyatt GH. Waking up from the DREAM of preventing diabetes with drugs. BMJ 2007;334:882-4. [PMID: 17463460 DOI: 10.1136/bmj.39169.447488.94] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
583 Desouza C. Does pioglitazone reduce carotid intima–media thickness in patients with type 2 diabetes mellitus? Nat Rev Endocrinol 2007;3:394-395. [DOI: 10.1038/ncpendmet0482] [Reference Citation Analysis]
584 Glycemic Management. Endocrine Practice 2007;13:16-34. [DOI: 10.1016/s1530-891x(20)46423-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
585 . Het effect van ramipril op de incidentie van diabetes. HUWE 2007;50:365-366. [DOI: 10.1007/bf03085171] [Reference Citation Analysis]
586 Davidson MB. Clinical Implications of the DREAM Study. Diabetes Care 2007;30:e45-e45. [DOI: 10.2337/dc07-0263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
587 Kanat M. Clinical implications of the DREAM study: response to Davidson. Diabetes Care 2007;30:e44; author reply e45. [PMID: 17468372 DOI: 10.2337/dc07-0245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
588 Vigil Medina L, López Jiménez M, García Carretero R. Recomendaciones específicas para el manejo del paciente con síndrome metabólico. Hipertensión 2007;24:101-109. [DOI: 10.1016/s0212-8241(07)72441-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
589 Freemantle N, Calvert M. Composite and surrogate outcomes in randomised controlled trials. BMJ. 2007;334:756-757. [PMID: 17431231 DOI: 10.1136/bmj.39176.461227.80] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
590 Reinli K, Guggenbühl B. Diabetesprimärprävention. Diabetologe 2007;3:105-112. [DOI: 10.1007/s11428-007-0115-5] [Reference Citation Analysis]
591 . Bibliography. Current world literature. Diabetes and the endocrine pancreas. Curr Opin Endocrinol Diabetes Obes 2007;14:170-96. [PMID: 17940437 DOI: 10.1097/MED.0b013e3280d5f7e9] [Reference Citation Analysis]
592 Hill J. Managing insulin resistance with oral hypoglycaemic agents. British Journal of Cardiac Nursing 2007;2:182-187. [DOI: 10.12968/bjca.2007.2.4.23454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
593 Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG, McFarlane P, Shepherd J, Cobbe S, Packard C. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007;56:984-91. [PMID: 17395744 DOI: 10.2337/db06-1256] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 6.2] [Reference Citation Analysis]
594 Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE. The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM? Blood Press 2006;15:260-2. [PMID: 17380842 DOI: 10.1080/08037050601121804] [Reference Citation Analysis]
595 Barnett AH. Summarising the use of thiazolidinediones with insulin. Diabetes & Vascular Disease 2007;7:75-80. [DOI: 10.1177/14746514070070020501] [Reference Citation Analysis]
596 Blicklé J. Protection bêta-cellulaire par les thiazolidinediones : quelles preuves aujourd’hui ? Médecine des Maladies Métaboliques 2007;1:79-85. [DOI: 10.1016/s1957-2557(07)88665-2] [Reference Citation Analysis]
597 Karuparthi PR, Yerram P, Lastra G, Hayden MR, Sowers JR. Understanding essential hypertension from the perspective of the cardiometabolic syndrome. J Am Soc Hypertens 2007;1:120-34. [PMID: 20409842 DOI: 10.1016/j.jash.2007.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
598 Gallwitz B. The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud 2006;3:208-16. [PMID: 17487346 DOI: 10.1900/RDS.2006.3.208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
599 Vingerhoeds ACM. Rosiglitazon in opmars. MFAM 2007;45:58-59. [DOI: 10.1007/bf03058943] [Reference Citation Analysis]
600 Doggrell SA. Rosiglitazone: rosy news for a thiazolidinedione. Expert Opinion on Pharmacotherapy 2007;8:265-268. [DOI: 10.1517/14656566.8.2.265] [Reference Citation Analysis]
601 Matthaei S. Typ-2-Diabetes. Diabetologe 2007;3:15-23. [DOI: 10.1007/s11428-006-0105-z] [Reference Citation Analysis]
602 Bilous R. DREAM and ADOPT: rosiglitazone does what it says on the packet. Diabet Med 2007;24:107-9. [PMID: 17257270 DOI: 10.1111/j.1464-5491.2007.02122.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
603 Davidson MB. Clinical implications of the DREAM Study. Diabetes Care 2007;30:418-20. [PMID: 17259522 DOI: 10.2337/dc06-2051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
604 Sämann A, Müller UA, Wolf G. Sicherheitsaspekte oraler Antidiabetika. Diabetologe 2007;3:31-36. [DOI: 10.1007/s11428-006-0102-2] [Reference Citation Analysis]
605 Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, Bornfeldt KE. Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 2007;56:1143-52. [PMID: 17259370 DOI: 10.2337/db06-0267] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
606 Wong ND. Metabolic syndrome: cardiovascular risk assessment and management. Am J Cardiovasc Drugs 2007;7:259-72. [PMID: 17696567 DOI: 10.2165/00129784-200707040-00004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
607 Bertomeu-gonzález V, Núñez Pernas D, Bertomeu Martínez V. Hipertensión arterial y dislipemia asociadas a diabetes mellitus. Papel de los PPAR. Enfoque terapéutico. Revista Española de Cardiología Suplementos 2007;7:20H-28H. [DOI: 10.1016/s1131-3587(07)75270-6] [Reference Citation Analysis]
608 Rosiglitazone, but not ramipril, prevents onset of type 2 diabetes in high-risk patients. Nat Rev Endocrinol 2007;3:6-6. [DOI: 10.1038/ncpendmet0357] [Reference Citation Analysis]
609 Devers M, Fisher M. Type 2 diabetes: getting off to a good start. Pract Diab Int 2007;24:6-8. [DOI: 10.1002/pdi.1033] [Reference Citation Analysis]
610 Kennedy L. Peroxisome Proliferator-Activated Receptor γ Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model. Yearbook of Endocrinology 2007;2007:23-24. [DOI: 10.1016/s0084-3741(08)70016-7] [Reference Citation Analysis]
611 Leahy J. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Yearbook of Endocrinology 2007;2007:60-63. [DOI: 10.1016/s0084-3741(08)70035-0] [Reference Citation Analysis]
612 Leahy J. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Yearbook of Medicine 2007;2007:471-474. [DOI: 10.1016/s0084-3873(08)70285-2] [Reference Citation Analysis]
613 Elliott W. Effect of Ramipril on the Incidence of Diabetes. Yearbook of Cardiology 2007;2007:79-81. [DOI: 10.1016/s0145-4145(08)70043-1] [Reference Citation Analysis]
614 Lau A, Harper W. Thiazolidinediones and Their Effect on Bone Metabolism: A Review. Canadian Journal of Diabetes 2007;31:378-83. [DOI: 10.1016/s1499-2671(07)14010-7] [Reference Citation Analysis]
615 Mcfarlane SI. Diabetes prevention between the HOPE and the DREAM. Therapy 2007;4:1-4. [DOI: 10.2217/14750708.4.1.1] [Reference Citation Analysis]
616 Liebson PR. DREAM and SPARCL. Preventive Cardiology 2007;10:48-51. [DOI: 10.1111/j.1520-037x.2007.5974.x] [Reference Citation Analysis]
617 Leahy J, Kennedy L. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Yearbook of Endocrinology 2007;2007:56-60. [DOI: 10.1016/s0084-3741(08)70034-9] [Reference Citation Analysis]
618 Merino Torres JF. Lo que el cardiólogo debe conocer sobre antidiabéticos orales e insulinas. Revista Española de Cardiología Suplementos 2007;7:49H-57H. [DOI: 10.1016/s1131-3587(07)75273-1] [Reference Citation Analysis]
619 Reaven GM. The Insulin Resistance Syndrome: Concept and Therapeutic Approaches. Pharmacotherapy of Diabetes: New Developments 2007. [DOI: 10.1007/978-0-387-69737-6_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
620 Pedersen O. Multifactorial Intervention in Type 2 Diabetes. Pharmacotherapy of Diabetes: New Developments 2007. [DOI: 10.1007/978-0-387-69737-6_14] [Reference Citation Analysis]
621 Vigil Medina L, López Jiménez M, García Carretero R. Recomendaciones específicas para el manejo del paciente con síndrome metabólico. Hipertensión y Riesgo Vascular 2007;24:101-109. [DOI: 10.1016/s1889-1837(07)71859-7] [Reference Citation Analysis]
622 American Diabetes Association. Standards of medical care in diabetes--2007. Diabetes Care 2007;30 Suppl 1:S4-S41. [PMID: 17192377 DOI: 10.2337/dc07-S004] [Cited by in Crossref: 1032] [Cited by in F6Publishing: 1146] [Article Influence: 64.5] [Reference Citation Analysis]
623 Dalfó A, Benítez M, Egocheaga M, Nevado A, Martín E, Bajo J, Domínguez M, Vázquez I, Ureña T, Sanchís C, Pepió J, Molina R, Iglesias J, Flores I, Bonet A. ¿Prevención de la aparición de diabetes mellitus con inhibidores de la enzima de conversión de angiotensina? FMC - Formación Médica Continuada en Atención Primaria 2006;13:648. [DOI: 10.1016/s1134-2072(06)71432-3] [Reference Citation Analysis]
624 Schaper F, Hanefeld M. Frauenärztliche Aspekte des metabolischen Syndroms. Gynäkologe 2006;39:944-952. [DOI: 10.1007/s00129-006-1911-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
625 Jawa A, Fonseca V. Metabolic Syndrome and Type 2 Diabetes Mellitus. Metabolic Syndrome and Cardiovascular Disease 2006. [DOI: 10.3109/9781420020601-4] [Reference Citation Analysis]
626 Ashcroft JS. Prevention of diabetes: lifestyle and metformin are the way forward. BMJ 2006;333:918-9. [PMID: 17068046 DOI: 10.1136/bmj.333.7574.918-d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Freeman PB. Diabetes: Knowing and preventing. Optometry - Journal of the American Optometric Association 2006;77:523-524. [DOI: 10.1016/j.optm.2006.09.010] [Reference Citation Analysis]
628 Heneghan C, Thompson M, Perera R. Prevention of diabetes. BMJ 2006;333:764-5. [PMID: 17038711 DOI: 10.1136/bmj.38996.709340.BE] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
629 Giri M. Medical management of obesity. Acta Clin Belg 2006;61:286-94. [PMID: 17240746 DOI: 10.1179/acb.2006.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
630 Conlon D. DREAM — a diabetes prevention study. Diabetes & Vascular Disease 2006;6:230-233. [DOI: 10.1177/14746514060060050501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
631 Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003;CD004094. [PMID: 14584004 DOI: 10.1002/14651858.cd004094.pub2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 110] [Article Influence: 4.3] [Reference Citation Analysis]